Linking topiramate exposure to changes in electrophysiological activity and behavioral deficits through quantitative pharmacological modeling by Callisto, Samuel
 
LINKING TOPIRAMATE EXPOSURE TO CHANGES IN 
ELECTROPHYSIOLOGICAL ACTIVITY AND BEHAVIORAL DEFICITS 
THROUGH QUANTITATIVE PHARMACOLOGICAL MODELING 
 
A DISSERTATION  
SUBMITTED TO THE FACULTY OF THE  
UNIVERSITY OF MINNESOTA 
BY 
 
Samuel Paul Callisto 
 
IN PARTIAL FULFILLMENT OF THE REQUIREMENTS  
FOR THE DEGREE OF 
DOCTOR OF PHILOSOPHY 
 
Dr. Susan E. Marino, Advisor 
Dr. Angela K. Birnbaum, Co-advisor 
 























 I could not have completed the monumental task of obtaining my doctorate 
without help from several individuals. First and foremost, I am so thankful for the support 
and guidance from my advisor Susan Marino. It is impossible to put into words how 
grateful I am for the flexibility and independence bestowed upon me by Dr. Marino in 
selecting my didactic coursework and directing my research into the areas which I was 
most interested in pursuing. I am also thankful for willingness to let me complete 
multiple summer internships, encouraging me to pursue various career development 
opportunities, and creating an environment in which creativity and experimentation was 
encouraged. 
  Many thanks are also due to my co-advisor Angela Birnbaum for continuously 
mentoring me in the art of conducting pharmacological research. Her insistence on 
developing well-rounded students provided me with the unique opportunity to experience 
nearly every aspect of a large-scale research project, including writing IRB applications, 
reviewing protocols, running samples on analytical instruments, and collaborating with 
scientists and physicians across the country. Dr. Birnbaum continually challenged me to 
think about the bigger picture and the context of my research, and in doing so helped me 
to become a better scientist. 
 I am forever grateful to Richard Brundage for encouraging me to sit in on his 
advanced pharmacometrics seminar during my first year in the PhD program. Although 
ii 
 
initially I was completely lost, he lit a fire in my mind and showed me a way to combine 
my various interests and skills. Dr. Brundage has constantly amazed me with his insight 
into extremely complex topics such as NONMEM error codes, gradient descent 
algorithms, interpersonal relationships, and leading a fruitful article discussion. 
 Many thanks are also due to Christopher Barkley and his unending willingness to 
help me improve both my technical writing skills and my understanding of how the brain 
works. Dr. Barkley’s mastery of crafting simple prose to illustrate complex ideas inspired 
me to think critically about each word before I even begin typing. My communication as 
not only a scientist, but also as a human, has been vastly improved through his patient 
correction of hundreds of pages of text. 
 As the sole biostatistician on my committee, a warm thanks is due to Mark Fiecas 
for his input on the many statistical analyses which went into this thesis. I came into his 
office with a research question, and no clue how to answer it, but he patiently helped me 
identify and test solutions. Through his generous donation of time and mental resources 
we were able to craft an analysis method that was both simple and insightful. 
 I would also like to thank members of our laboratory group for their contributions 
to my training, particularly Ilo Leppik for his insights into the patient experience and 
partially funding my trip to Uppsala University to receive pharmacometric training, and 
Rory Remmel for teaching me about medicinal chemistry and drug metabolism both in 
and out of the classroom. I would also like to thank Sai Praneeth Bathena for his 
assistance in developing the models presented in this thesis, and Taraswi Mitra Ghosh for 
iii 
 
collaborating with me on pharmacogenomic research projects conducted in Dr. 
Birnbaum’s lab. Finally, thanks to Michaela Roslawski, Alyssa Johnson, and Rachel 
Moniz for handling all the behind-the-scenes work involved in running the research 
laboratory. 
 The University of Minnesota College of Pharmacy is currently ranked the #2 
pharmacy school in the country, and that is due in large part to the significant efforts of 
the amazing faculty. Thank you so much to all the professors who trained me through 
didactic and experiential learning opportunities. The training that I received during my 
time was better than anything I could have imagined prior to entering the program. A 
special thanks is due to Pamala Jacobson for allowing me to pursue pharmacogenomic 
research through wet laboratory experience during my first summer in the program and 
allowing me to assist in organizing the first two Precision Medicine Conferences hosted 
by the University of Minnesota College of Pharmacy. Her candor and enthusiasm for 
both research and social activities were a constant source of joy during my time in the 
program. I would also like to extend additional thanks to both L’Aurelle Johnson and 
Mahmoud Al-Kofahi, whose doors were always open. Their willingness to answer 
questions and help me to develop professionally and personally whenever I wandered in 
was greatly appreciated. Many thanks also to the administrative staff for the College of 
Pharmacy, especially Mary Moreno Lien, Dede Johnston, Becky Palapala, Carolyn 
Chase, Diane Blumenfeld, Susan Williford, Erin McGonagle, and Carol Ann Dickinson 
for all their support and help navigating the maze of graduate school. 
iv 
 
 Two deeply formational experiences during graduate school were the summer 
internship opportunities which I completed at OneOme and AbbVie. Thank you to Dione 
Bailey, Ross Higgins, Paul Owen, Sandy Goss, Megan Gibbs, Michael Casey, and 
everyone else who I was fortunate to work with during these summers. As mentioned 
previously, I am exceedingly appreciative to Susan Marino for allowing me to take time 
away from researching to intern with these companies as I attempted to discover the ideal 
path for my post-graduate school career. 
 Graduate school has been the most challenging yet rewarding five years of my life 
thus far. Very few individuals understand the 24/7 stressors; however, I am extremely 
thankful for the support of my fellow ECP graduate students. It is amazing how many 
great people have been part of this program, and I am humbled to have the experience of 
learning with and from all of them. I would like to especially thank my dear friend 
Natalie Schmitz, the only other student in the 2014 cohort. I could not have asked for a 
better person to spend most of my days with during the first few years of this program, 
and am continuously inspired by her determination, kindness, and humility. We did it! I 
would also like to thank Irene Vuu, whose unending positivity has always brightened my 
days even during the most difficult times. Her constant supply of sweets was always 
appreciated and usually necessary. I would also like to point out one senior student who 
played a humongous role in my professional development, Ali Al-Hadab. I am so 
thankful that we were able to experience coinciding summer internships in Chicago, and 
appreciative of his time spent teaching me how much can be accomplished using R and 
v 
 
helping me to understand the nuances of pharmacometrics. Many, many thanks are due as 
well for the mentorship that I received from Malek Okour, Chay Ngee-Lim, Ghada 
Ahmed, Mariam Ahmed, Kinjal Sanghavi, and Youssef Roman. 
 Many teachers encouraged the love of learning which drove me to devote 21 
years of my life to the pursuit of knowledge through formalized education. In addition to 
the faculty members at the University of Minnesota College of Pharmacy mentioned 
previously, I would also like to specifically thank Lori Balza, Steve Provinzino, Bill 
Rahn, Roald Sateren, Rob Gordon, Deb Martin, and Jaime Mueller. 
 Finally, I would not have completed this arduous journey without the support of 
my family and friends. I have been blessed with such a wonderful network of people who 
have brought so much joy into my life. There are too many individuals to name, but you 
all know who you are. Thank you to my family for continued encouragement and 
support. My mother has been a role model of hard work throughout my entire life, and I 
am grateful for all the sacrifices which she made to allow me to be here today. Last but 
not least, thank you so, so much to my amazing wife Samantha. Since the day we met she 
has inspired me to reach for the stars and has supported me throughout this entire process. 






 Topiramate is a broad-spectrum anti-epileptic drug used to treat a variety of 
conditions, including epilepsy, migraine, substance abuse, mood, and eating disorders. 
We investigated the effects of topiramate on the working memory system using 
population pharmacokinetic-pharmacodynamic modeling and unsupervised machine 
learning approaches. Working memory is the capacity-limited neurocognitive system 
responsible for simultaneous maintenance and manipulation of information in order to 
achieve a goal. Behavioral and electrophysiological indices of working memory function 
were measured using data collected during a double-blind, placebo-controlled crossover 
study in healthy volunteers. Subjects completed a Sternberg working memory task, 
during which accuracy and reaction time were measured, while subjects’ EEG was 
recorded. 
 A pharmacokinetic-pharmacodynamic model was constructed which 
demonstrated that accuracy decreased linearly as a function of plasma concentration, and 
that the magnitude of individual deficits was predicted by working memory capacity. A 
separate pharmacokinetic-pharmacodynamic model was developed which showed that 
spectral power in the theta frequency band (4-8 Hz) recorded during the retention phase 
of the Sternberg task increased as a function of plasma concentration. Furthermore, a 
mixture model identified two subpopulations with differential sensitivity in topiramate-
induced theta reactivity. In the subpopulation defined by lower reactivity, reaction times 
were 20% slower than in the high theta reactivity subpopulation.  
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 Principal component regression was used to quantify the relationship between 
changes in multiple measures of electrophysiological activity and behavioral deficits. 
Theta power during retention was found to be the best predictor of topiramate-related 
behavioral deficits. Performance on another working memory task, Digit Span Forward, 
was also predicted by theta power during retention, as well as alpha (8-12 Hz) power 
during encoding and retrieval stages.  
 In conclusion, two treatment-independent factors that predict differences in 
behavioral and electrophysiological responses to topiramate administration were 
identified: working memory capacity and theta reactivity. Future research will be needed 
to determine the utility of these demographic factors in predicting risk of cognitive side 
effects in patients eligible for treatment with topiramate. 
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1.1 Adverse Drug Effects on Cognition 
1.1.1 Impact of drug-induced cognitive impairment 
Numerous drug classes impair cognition as a side effect, causing a significant 
negative impact on patient quality of life, decreasing adherence, and leading to treatment 
discontinuation (1, 2). Some drug classes commonly associated with cognitive side 
effects include anticholinergics (3, 4), benzodiazepines (5, 6), anti-cancer agents (7-10), 
and antiepileptic drugs (AEDs) (11-13). In this thesis, I focus specifically on the 
cognitive side effects caused by AEDs, with the ultimate goal of developing a 
methodological approach that can be applied to additional drug classes in the future.  
Epilepsy pathophysiology is associated with neuropsychological dysfunction (14-
16), and cognitive side effects of AEDs impose a significant burden on these already at-
risk patients. The cognitive adverse event profile of a given medication is one of the 
strongest predictors of health-related quality of life for patients taking AEDs (17). The 
risk of side effects outweighs the benefits of seizure remission for many patients 
surveyed about AED preferences, with already-diagnosed patients citing memory 
problems as the side effect they are most concerned about (18). Moreover, when given 
the choice between two drugs with different side effect profiles, women of childbearing 
age ranked memory problems as a more important factor than seizure reduction or 
increased risk of fetal abnormalities (18). Cognitive side effects caused by AEDs can be 
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particularly debilitating for patients with epilepsy, who are at increased risk for cognitive 
impairment caused by epilepsy pathophysiology (19-21). Impairment of cognition can be 
especially problematic in vulnerable populations. For example, children with epilepsy 
may experience reduced learning ability due to AEDs, exacerbating academic 
underperformance relative to healthy peers related to their diagnosis (22). The potentially 
additive effects of cognitive impairments caused by pathophysiology and those associated 
with AEDs provide an explanation for why so many patients with epilepsy are concerned 
about the risk of medication-related side effects. As a consequence of this interaction 
between pathology and adverse drug effects, a great deal of research has investigated 
differences in the occurrence and severity of cognitive impairment within the AED class 
(23-34). I will focus on topiramate specifically in this thesis because it has consistently 
been shown to cause more intolerable adverse effects on cognitive than other AEDs, with 
a unique pattern of deficits in the language system (11, 23, 28-34). 
1.2 Topiramate 
1.2.1 Discovery and approved indications 
 Topiramate (TPM) is a second-generation AED developed in 1979 by Dr. Bruce 
Maryanoff while working at McNeil Laboratories (35). The base structure is a sulfamate 
derivative of D-fructose. Although the medicinal chemists were intending to develop a 
substituted carbohydrate that could inhibit fructose-1,6-bisphosphatase for diabetes 
management, neuropharmacologists in the company believed that the molecule may have 
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anticonvulsant properties due to its structural similarity to acetazolamide (35). It was 
approved by the U.S. Food and Drug Administration (FDA) in 1996 for adjunctive 
treatment of generalized tonic-clonic and focal impaired awareness (previously complex 
partial) seizures (36, 37). More recently topiramate has been approved for adjunctive 
treatment of seizures associated with Lennox-Gastaut syndrome, and monotherapy 
treatment of generalized tonic-clonic and focal impaired awareness seizures (38). 
Topiramate is also approved by the FDA for migraine prophylaxis in adults and children 
over 12 years old (38), and is commonly used off-label for mood disorders (39, 40), 
substance abuse disorders (41-45), and weight loss (46). In 2012 a combination drug 
containing topiramate and phentermine was approved as a prescription anti-obesity 
treatment (47, 48). 
1.2.2 Previous studies of topiramate-induced cognitive side effects 
 A subset of 10 to 40% of patients taking TPM experience some form of cognitive 
side effect, with the most common complaint described as “word-finding difficulties” 
(23, 49-52). The incidence of these impairments occurs disproportionately in patients 
taking TPM compared to other AEDs (28, 30, 31, 33), causing patients on the drug to 
discontinue treatment at a higher rate (28, 30). Topiramate administration negatively 
impacts multiple cognitive domains, including language, attention, perceptual motor 
function, and short-term and working memory (11, 33, 53). These impairments have been 
assessed using a variety of neuropsychological tests, including, but not limited to, the 
Trail Making Test (33, 54-56), Controlled Oral Word Association test (COWA) (23, 34, 
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53, 55-60), Symbol Digit Modalities Test (SDMT) (23, 34, 56, 60, 61), Digit Span (33, 
53, 55-57), Token Test (53, 57), and Story Recall (53, 56, 59, 60). The effect of TPM on 
performance on two tests, the COWA and SDMT, have been previously modeled using a 
pharmacostatistical approach similar to the one described in detail later in this chapter. 
Therefore, I will provide more detail on previous studies incorporating these two 
neuropsychological tasks below. 
 The Controlled Oral Word Association Test, or COWA, is commonly used to 
assess verbal fluency, requiring subjects to spontaneously produce words in a defined 
category, such as words beginning with a certain letter or belonging to a specified 
semantic category such as animals (62-65). Studies have shown that performance on the 
COWA is significantly impaired by TPM administration, leading subjects to produce 
fewer correct responses in both healthy volunteers (28, 56, 58, 59) and epilepsy patients 
(23, 57). 
 The Symbol Digit Modalities Test (SDMT) is a task used to assess perceptual 
motor function, in which subjects substitute as many values as they can in 90 seconds 
using a provided decoding key which matches geometric figures to numbers (66). SDMT 
score is decreased after TPM administration in healthy volunteers at both low (56) and 
high doses (28) in a concentration-dependent (61) fashion, and a study comparing focal 
epilepsy patients receiving TPM to those receiving valproate found SDMT performance 
to be worse in patients taking TPM (23). The relationship between concentration and the 
5 
 
severity of impairment seen on the SDMT has been observed in many tasks, discussed 
further in the following section. 
1.2.3 Factors known to affect the severity of TPM-induced cognitive impairment 
 Although it is currently impossible to accurately predict which individuals will 
experience cognitive deficits resulting from TPM administration, previous studies have 
identified various treatment-related factors which appear to be associated with the 
severity of side effects. Below, I review the literature for the three most commonly cited 
of these factors: titration rate, drug exposure, and concomitant medications.  
 Titration rate is a term that refers to the speed at which daily doses are increased 
to reach the amount necessary to provide therapeutic benefit, with various dose titration 
schedules recommended for several antiepileptic drugs (67). The recommended titration 
rate for patients taking TPM as monotherapy to treat epilepsy is a 50 mg/day starting 
dose increased by 50-100 mg/day each week to a target dose of 400 mg/day, while the 
titration rate for patients taking TPM for migraine prophylaxis is a starting dose of 25 
mg/day increased by 25 mg/day each week to a target dose of 100 mg/day (38). An early 
study of the effects of TPM on cognition performed by Biton et al. compared the 
frequency of adverse cognitive events between the recommended titration schedule for 
epilepsy and a “fast” titration schedule, with an initial dose of 100 mg/day increased by 
100-200 mg/day each week (68). Despite equivalent reductions in seizure frequency 
between the two groups, adverse effects were significantly more frequent in the fast 
titration group, with a greater proportion of patients withdrawing or discontinuing 
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compared to the patients being titrated at the recommended rate (68). These findings have 
been reproduced in a similar study looking at the recommended migraine prophylaxis 
titration rate (69), as well as in pediatric patients taking adjunctive TPM for refractory 
epilepsy (70), though these findings have not been consistently replicated (cf. (51, 71)). 
As a consequence of these failures to replicate, the influence of titration rate on the 
incidence of TPM-induced cognitive impairment remains unclear. 
 Another factor frequently reported to play a role in affecting the incidence and 
severity of TPM adverse effects is exposure, generally described by either the daily dose 
of the drug or plasma concentration. Studies have shown a relationship between TPM 
plasma concentration and the magnitude of deficits on tests of psychomotor speed (56, 
61), verbal fluency (56, 58), and working memory (56, 59, 72) in healthy volunteers. 
However, studies in patients with epilepsy have found that the degree of impairment is 
not always associated with differences in plasma concentration (55, 57) or dose (33, 55). 
These seemingly contradictory findings on the relationship between exposure and 
behavior when comparing healthy volunteers and patients with epilepsy are clear 
indicators that exposure alone is not always a reliable predictor of TPM-induced deficits. 
 Finally, patients taking concomitant medications, especially other AEDs, are 
frequently shown to be at increased risk of experiencing TPM-induced cognitive 
impairment. In an observational study seeking to identify predictors of cognitive side 
effects of AED therapy, the two significant predictors identified during follow-up were 
lack of intellectual disability and polytherapy (11). Indirect evidence of this relationship 
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has also come from studies showing that patients taking concomitant AEDs may be more 
likely to discontinue TPM ((73), cf. (49)). A study in patients showed that individuals 
performed worse on a neuropsychological battery when taking the AED valproate in 
addition to TPM compared to patients taking TPM alone (57). Lastly, an indication that 
there may be an interaction between concomitant medications and exposure comes from a 
study which showed that decreasing the dose of concomitant AEDs when starting TPM, 
thereby lowering overall exposure, decreased discontinuation due to adverse events (74). 
 Although the previously discussed factors appear to play some predictive role, the 
inconsistencies across studies indicates that additional research is required. One potential 
source of these contradictory findings is the variability in test batteries used to assess 
cognitive function across studies. In this thesis I will be focusing specifically on the 
effect of TPM on working memory function, a cognitive system imperative for daily 
function which is profoundly impacted by TPM administration. Limiting my 
investigation to working memory is facilitated by a cognitive task which arguably reflects 
only activity in this system. Below I illustrate the importance of working memory in daily 
activities with the goal of motivating the choice of this specific cognitive system for my 
investigations into TPM’s effects on cognition. 
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1.3  Working Memory 
1.3.1 What is working memory? 
 Working memory (WM) is the limited-capacity neurocognitive system 
responsible for simultaneously maintaining and manipulating information in order to 
complete a task. A fundamental property of the WM system is that it is highly capacity-
limited in terms of how much information can be stored simultaneously, and there is a 
large amount of variability in capacity between individuals. Crucially, these inter-
individual differences are meaningful: measures of capacity correlate with fluid 
intelligence (75, 76), reasoning ability (77), processing speed (78), and predict academic 
attainment in both math and reading (79, 80). The association between WM and these 
other measures of high-level function illustrate the important role this system plays in 
daily activity; detrimental effects to this system could cause a variety of behavioral 
manifestations. Researchers investigating the capacity of WM originally argued for a 
consistent limit to the number of items retained regardless of modality, first thought to be 
seven (81), but later revised down to four (82). This revised estimate reflects the ability to 
“chunk” information together while stimuli are being stored (83, 84), with this ability 
dependent upon both the modality (85) and compressibility of information being stored 
(86). Common measures of capacity include, among others, reading span (87), operation 
span (88), Pashler’s k (89), and Cowan’s k (90), which each provide slightly different 
estimates of capacity. The differences in the method used for measuring WM function 
and capacity will be discussed in more detail in Chapter 2.  
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 The WM system was initially described using a series of interconnected 
components, each specialized to complete a discrete task. In this model, the visuospatial 
sketchpad stores and manipulates visuo-spatial information, the phonological loop 
performs the same function for auditory information, and the episodic buffer serves to 
integrate complex information from various modalities including the two previously 
mentioned stores and long-term memory. These storage components were proposed to be 
managed and coordinated by a control system termed the central executive (91, 92). More 
recently, competing views of the structure of the WM system have emerged to describe in 
a more general, modality-independent way, how external information is processed (93). 
Rather than using modality-specific systems to store specific types of information, these 
models rely upon shifting attentional focus to information stored in long-term memory 
(82, 93-96). Although a consensus has not yet been reached regarding the architecture of 
WM, this discussion lies outside the scope of this thesis and will bear little impact on the 
outcomes described herein. 
 One of the many methods of assessing WM for an individual is the change 
detection task: individuals are shown some cue stimulus (e.g. a pattern of filled cells or a 
string of syllables) for a brief period of time, referred to as the “encoding” phase, as it is 
the point at which the stimulus is encoded into memory. The cue stimulus then disappears 
for a brief period, termed the “retention” phase. Shortly thereafter a probe appears, and 
subjects must respond whether the item has changed or is identical to the original cue. 
This final phase is called the “retrieval” stage, as the original cue stimulus must be 
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recalled from memory and compared to the probe stimulus. Throughout this thesis I will 
be referring to data collected using a variation of the change detection task, a modified 
Sternberg WM task, the structure of which enables investigation of these three phases, 
while enabling comparison of the effect of cognitive insult across multiple memory loads 
(97). This task is commonly used in WM studies, and will be described in detail in the 
second chapter of this thesis. 
1.3.2 Effects of topiramate on working memory 
 Multiple studies have shown that TPM negatively impacts performance on tasks 
that assess some aspect of working memory function, including digit span (33, 53, 55-
57), Symbol Digit Modalities Test (SDMT) (23, 34, 56, 61), and the Trail Making Test 
(TMT) (33, 54-56). More recently it has been shown that TPM impairs performance on 
the Sternberg WM task (59, 72). These studies suggest that TPM causes severe WM 
impairments regardless of the task used to assess WM function. Investigation of 
electrophysiological indices of WM function, discussed in the next section, may lead to 
additional insights otherwise undetected by behavioral differences alone. 
1.4 Electrophysiological Indices of Working Memory 
1.4.1 Electrophysiology basics 
 Electroencephalography (EEG) is a method of recording the difference in 
electrical activity between two locations on the surface of the scalp which is commonly 
used as an index for underlying cognitive processes. These measurements reflect the 
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activity of a subset of the neuronal population adjacent to the electrode, with excitatory 
postsynaptic potentials in the cerebral cortex being the major contributor to electrical 
activity (98, 99). Specifically, the measurements from the surface of the scalp reflect the 
superposition of all extracellular activity, reflecting spatial alignment and temporal 
synchrony of neuronal firing. Memory processes occur in the span of milliseconds, 
leading many researchers to employ the millisecond temporal precision of the EEG 
technique to investigate these processes (98).  
 EEG data reflects changes in the electrical activity at a given electrode throughout 
the recording period, resulting in a time-ordered series of voltage measurements. Time-
based analyses of EEG can be performed, such as event-related potentials; alternatively, 
the data can be converted into the frequency domain for analysis, the method applied in 
this thesis, using Fast Fourier transforms. The data is represented by the superposition of 
multiple oscillation frequencies following this transformation (100). EEG frequency-
domain analysis is often split into five canonical nonoverlapping oscillation frequency 
bands: delta (0.1-3 Hz), theta (4-8 Hz), alpha (8-12 Hz), beta (12-30 Hz), and gamma 
(>30 Hz), each of which has been associated with various cognitive or motor functions or 
with different states of arousal. A common measurement extracted from the power 
spectrum is the average band power, or simply “power,” calculated by taking the area 
under the power spectrum density curve (100). Power can be thought of as a measure of 
the sum of electrophysiological activity across multiple cells firing at different rates 
within a defined time window (101). Each individual has a peak frequency for a given 
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band, which is the frequency with the highest power in the defined frequency range. Each 
of these oscillations has an associated amplitude, the height of the waveform, as well as 
phase, the position of the oscillation at time zero. The work presented in this thesis will 
focus on power changes occurring in the theta and alpha band during performance on the 
Sternberg WM task. Associations between activity in these frequency bands and 
cognition, particularly WM function, is summarized in the following section. 
1.4.2 Functional interpretation of theta and alpha band activity 
 Activity in the theta and alpha frequency bands are highly sensitive to WM 
function. During WM task performance, theta activity increases in areas involved in task 
performance, thought to reflect mental effort related to task completion; simultaneously, 
alpha activity decreases in these same areas involved in task completion and increases in 
task-irrelevant areas, hypothesized to correspond to suppression of extraneous neuronal 
activity which may interfere with memory processes (101-104). However, theta and alpha 
activity is not only observed during WM function. 
 Much research has been conducted on the role that theta oscillations (4 – 8 Hz) 
play in cognitive processes. Activity in the theta frequency range is related to memory 
processes in humans (101, 105-108), as well as spatial navigation (109-112) and 
internally-directed attention or meditation (113-116). During WM processes specifically, 
theta power changes are observed during the encoding (117, 118), retention (104, 117-
120), and retrieval (118, 119) stages of a WM task. Increased power in the theta band has 
been shown to increase as a function of memory load during performance on Sternberg 
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WM tasks (121, 122), thought to reflect sustained mental effort (104, 123-125). In 
addition to the activity observed in the theta band, alpha band activity is also sensitive to 
WM function. 
 Activity in the alpha band (8 – 12 Hz) increases during eyes-closed resting 
conditions and decreases during mental activity and eyes-open resting conditions (126-
128). Researchers have interpreted increased alpha activity as a marker for the “default 
mode network,” the neuronal activity present in the brain when it is not focused on a task 
(129-131), as well as reflecting inhibition of cortical areas (132, 133). Tasks with 
lateralized stimuli illustrate this role of alpha activity, during which alpha power 
decreases in the hemisphere contralateral to the attended stimulus relative to the 
ipsilateral hemisphere for both visual (134) and sensorimotor (135) tasks. During WM 
tasks, alpha power decreases with memory load in posterior regions of the scalp, thought 
to correspond to release of inhibition of areas involved in task performance (136, 137). At 
the same time, increases in alpha power and amplitude increase with memory load over 
task-irrelevant regions, reducing extraneous, non-task-related processes (104, 124, 137-
142). Due to their sensitivity to WM function, activity in the theta and alpha frequency 
bands seemed a likely target for TPM-induced cognitive impairment. 
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1.5 Population Pharmacokinetic-Pharmacodynamic Modeling 
1.5.1 Population pharmacokinetic modeling 
 Population pharmacokinetic modeling is a pharmacostatistical approach which 
enables identification of parameters which quantify the time course of drug exposure in 
individuals within a population. Studies with an unbalanced design resulting in differing 
numbers of observations between patients can easily be analyzed using non-linear mixed 
effects models, a type of regression model that includes population-level parameters 
(“fixed effects”), and individual-level variability parameters (“mixed effects”). This 
facilitates the ability to leverage data at the population level to inform predictions for an 
individual. For the same reason these models can utilize both sparse and rich individual 
patient data within the same dataset, allowing more data to be included in analyses 
compared with other analytic techniques (143). Patient demographics can easily be 
included into these models to account for variability between individuals, such as drug 
metabolism differences due to weight, age, or altered kidney and liver function, among 
others. This approach is widely-used in drug development and has become an integral 
part of data contained in new drug applications by both the Food and Drug 
Administration (FDA) (144) and European Medicines Agency (EMA) (145). These 
models may also be combined with models of drug effect, or pharmacodynamics, which 
will now be described. 
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1.5.2 Pharmacokinetic-pharmacodynamic modeling 
 Population pharmacokinetic-pharmacodynamic (PK-PD) models combine 
population pharmacokinetic models with population-level descriptions of drug effects, or 
pharmacodynamics. This approach allows quantification of drug effect by predicting drug 
exposure at a specific time for each individual, including plasma concentration or AUC, 
even if patient samples were not obtained at that time. PK-PD models can be useful for 
assessing therapeutic effect across a range of drug exposures. In this thesis, I am applying 
PK-PD modeling to assess drug effects on working memory using behavioral and 
electrophysiological indices of cognitive function. Previous studies have used gross 
behavioral measures that reflect the sum of multiple cognitive systems, including sedative 
effects (146), measures of perceptual motor speed (147), and results of 
neuropsychological tests which can be interpreted to be measuring multiple cognitive 
domains (58, 61, 148). For example, the SDMT has been previously described as 
measuring cognitive processing speed (149, 150), motor speed (151), visuomotor 
coordination (152), working memory (152), and attention (150, 151). In contrast, this 
study uses the Sternberg WM task, a task which has been used for decades to measure 
WM function. Furthermore, electrophysiological correlates of impairment have not 
previously been used to quantify the exposure-response relationship between TPM 
plasma concentration and cognitive deficits. 
 Previous studies have utilized this approach to explore the exposure-response 
relationship between TPM and performance on tasks measuring verbal fluency and 
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perceptual motor speed/working memory, as measured by the COWA and SDMT 
neuropsychological tasks, respectively. A pharmacokinetic-pharmacodynamic model 
from a study performed in healthy volunteers found SDMT scores were on average 
reduced by 25% from baseline at the EC50 of 2.85 ug/mL in a group of healthy 
volunteers administered a single dose of either 50, 100, or 200 mg of TPM (61). Ahmed 
et al. used a population approach to investigate the effects of TPM on verbal fluency 
measured using COWA, with the model predicting a decrease of 14.5% score with each 
ug/mL of TPM, equating to a 27% reduction in score at the average observed maximum 
plasma concentration resulting from a 100 mg dose of TPM (58). The studies presented 
in this thesis build upon the findings from these previous studies by examining the effects 
of TPM specific to the WM system, as measured using behavioral and 
electrophysiological results from a modified Sternberg WM task. Previous studies using 
EEG measurements as a pharmacodynamic endpoint reveal mechanistic insights uniquely 
identified using electrophysiological data. 
 In chapter three of this thesis, measurements calculated from 
electroencephalogram (EEG) recordings are used as the pharmacodynamic endpoint in a 
PK-PD model. There are various methods for analyzing EEG data and converting it to a 
scalar value that is amenable to PK-PD modeling, with most studies using band power as 
the PD measure (153-161). Older studies more commonly relied upon measures of 
amplitude, possibly due to the computational burden associated with integrating across 
frequency ranges to calculate power (162-166); however, some contemporary studies still 
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use this measure (167, 168). A related measurement, waves per second in the beta 
frequency, was also utilized in multiple pharmaco-EEG studies (169-171). This research 
motivated the choice of amplitude or band power as the optimal EEG measurement to use 
as the pharmacodynamic endpoint in our PK-PD modeling approach. After demonstrating 
the relationship between concentration and changes to both behavior and 
electrophysiology, a third aim of this thesis was to link electrophysiological changes to 
behavioral changes, which will be accomplished using an adapted machine learning 
approach, detailed in the following section. 
1.6 Machine Learning Approaches in Drug Research 
1.6.1 Definition of Terms 
 The term “machine learning” was first defined as “the field of study that gives 
computers the ability to learn without being explicitly programmed” by Arthur Samuel in 
his seminal 1959 paper “Some studies in machine learning using the game of checkers” 
(172). A more contemporary definition was given by Tom Mitchell: “A computer 
program is said to learn from experience E with respect to some class of tasks T and 
performance measure P, if its performance at tasks in T, as measured by P, improves with 
experience E” (173). This term has enjoyed recent popularity with companies in various 
fields touting the power of machine learning to revolutionize their industry. In the area of 
precision medicine, this technique has been applied to predict susceptibility of cancers to 
novel therapeutics (174-176), empirically identify disease subtypes through biomarker 
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clustering (177-180), and develop individualized predictive models of disease 
progression (181-183). Despite its myriad applications, a simple idea underlies this 
approach: statistical models can generate predictions through the use of algorithms which 
can detect covert patterns in large data sets. Machine learning is divided into two broad 
categories: supervised algorithms, which use a predefined outcome to improve prediction 
accuracy, or unsupervised algorithms, which identify structure in a dataset through 
variable clustering when outcomes are undefined. 
1.6.2 Justification for Machine Learning Approach 
Although there are various methods of machine learning which could be applied 
to pharmaceutical research, one goal of this thesis is to identify electrophysiological 
indices associated with behavioral measures of cognitive impairment. Because there are 
innumerable measures which can be extracted from EEG data, the goal of using machine 
learning in this thesis is to find an empirical solution for identifying underlying structure 
in the EEG data, especially relations between measurements obtained at different stages 
of the memory process and in different frequency bands. To accomplish this task, an 
unsupervised machine learning algorithm, principal component analysis (PCA), was 
employed. 
1.6.3 Principal Component Analysis 
Principal component analysis (PCA) takes a set of possibly correlated datapoints 
and utilizes an orthogonal transformation to create weighted composites of the data called 
principal components (PCs). Use of these composite measures allows for reduction of 
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dimensionality by using a small set of composites, rather than every variable. Many 
disciplines utilize this statistical method for dimensionality reduction. Recently, this 
technique is in vogue in genetics under the alias “gene shaving”, where it is used to 
uncover latent associations in large microarray datasets (184). The variability explained 
by each component is maximized when generating the weighting applied to each 
variable, with the first PC describing the largest amount of variability. Each PC is 
orthogonal to the next, allowing interpretation of each PC independently. Once the PCs 
are generated, a subset of the PCs can be selected, which greatly reduces the number of 
variables used to describe a phenomenon. In addition to dimensionality reduction, PCA 
also identifies structure within a dataset by clustering variables which jointly explain a 
proportion of variability. These related outcomes illustrate the utility for this approach in 
selecting a subset of measurements derived from the EEG data collected during our 
study, while simultaneously identifying otherwise unseen relationships between 
measures. 
1.7 Scope of Dissertation Work 
 The research outlined in this thesis utilizes PK-PD modeling to quantitatively link 
TPM exposure to various measures of cognitive side effects purportedly caused by this 
drug. The relationship between behavioral outcomes and electrophysiological responses 
will be characterized by creating a set of models that relate these changes both to each 
other and to TPM exposure, as measured by plasma concentration. Chapter 2 focuses on 
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development of a population PK-PD model of behavioral changes to performance on a 
modified Sternberg working memory task after topiramate administration. Chapter 3 
discusses development of a population PK-PD model which includes theta band power as 
the pharmacodynamic marker for impairment. Finally, a machine learning algorithm is 
used in Chapter 4 to assess the relationship between these models by identifying 
composite electrophysiological measures associated with behavioral changes induced by 
TPM administration. Conclusions and proposed future directions of research are outlined 
in the final chapter. 
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 As mentioned in the introduction chapter, topiramate (TPM) administration is 
associated with deterioration in several cognitive domains including verbal fluency, 
verbal learning, and both short-term and working memory (1-3). Because of the 
prevalence of these impairments, patients discontinue topiramate at a higher rate than 
other AEDs, with many citing cognitive side effects as the primary reason for 
discontinuation (4-7). Although these patterns of TPM-related cognitive deficits have 
been described relatively well, we still lack a complete understanding of what makes 
certain individuals more susceptible to these side effects. Two potential factors, working 
memory capacity and drug exposure, have recently been identified to have a degree of 
predictive power with regard to the severity of TPM-related cognitive impairment. 
 Working memory (WM) is the capacity-limited neurocognitive system that 
functions to simultaneously store and manipulate information over short time intervals in 
order to achieve a behavioral goal (8, 9). Estimates of working memory capacity (WMC) 
positively correlate with complex cognitive functions such as fluid intelligence (10, 11), 
math and reading skills (12, 13), and reasoning and decision making (14, 15). Various 
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tasks have been employed in previous studies to estimate an individual’s WMC, 
including, but not limited to, complex span (16-20) and change detection tasks (21-23). In 
this study we estimate individual WMC using a change detection task with three memory 
loads, allowing us to investigate differences in the severity of impairment occurring as a 
function of memory load.  
 A second factor which may play a role in modulating the severity of TPM-related 
cognitive deficits is drug exposure (24-27); however the relationship between exposure 
and performance has not been consistently replicated across all studies (28-30). Due to 
inability to measure concentrations at the site of action in the brain, plasma concentration 
is frequently used as a surrogate measurement of drug exposure. Other measures related 
to exposure are also associated with side effect severity, including titration rates (31-34) 
and concomitant AEDs (5); however, associations between drug exposure and side 
effects have not been consistently replicated (7, 35). These inconsistent findings indicate 
that treatment-related factors such as drug exposure are likely not the only variable 
driving individual susceptibility to TPM-related cognitive impairment. 
 Evidence from a recent study showed that both WMC and plasma concentration 
both make contributions to modulate the severity of TPM-related cognitive deficits. In 
that study, individuals with high WMC experienced more severe deficits which occurred 
as a function of plasma concentration, while low WMC individuals’ impairments were 
not associated with plasma concentration (26). In the work presented here, we extend 
these findings by using a non-linear mixed effects model to better characterize the 
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relationship among WMC, drug concentrations, and the severity of TPM-related 
cognitive impairment. As such, the goal of this study was to determine the concentration-
dependent impairment of WM function after accounting for differences in WMC between 
individuals.  
2.2 Methods  
2.2.1 Study design 
 Forty-six healthy volunteers completed a randomized, double-blind, placebo-
controlled crossover study conducted at the University of Minnesota and approved by the 
University of Minnesota Institutional Review Board. Subjects provided written informed 
consent and then completed a modified Sternberg WM task (36) during the initial no-
treatment baseline visit. Following completion of the baseline session, subjects were 
assigned to receive TPM, lorazepam, and placebo once each in one of six possible 
treatment sequences. On each subsequent visit the subject received a single dose of their 
assigned drug for that session, either TPM (100, 150, or 200 mg), inactive placebo, or 
lorazepam (2 mg; lorazepam results reported elsewhere). Visits were separated by at least 
two weeks to prevent carry-over effects from previous sessions, with an additional post-
baseline session completed after the three treatment visits. All study drugs were stored at 
the University of Minnesota Investigational Drug Services pharmacy and administered by 
nurses trained on the study protocol. Blood samples were collected prior to dosing and 
approximately 0.5, 1.5, 2.5, 4, and 6 hours after dosing for quantification of TPM plasma 
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concentrations (37). Subjects returned for an additional blood draw after each treatment 
session which was randomly assigned to occur at 24, 48, 72, or 96 hours after dosing. 
Exclusion criteria included the following: cardiovascular, endocrine, hematopoietic, 
hepatic, neurologic, psychiatric, or renal disease; a history of drug or alcohol abuse 
within the past five years; the use of concomitant medications known to affect cognitive 
function (including antidepressants, anxiolytics, psycho-stimulants, analgesics, and 
antipsychotics); prior history of hypersensitivity to TPM, lorazepam, or related 
compounds; a positive pregnancy test (administered to all females before the start of each 
study visit); use of any investigational drug within the previous thirty days; a native 
language other than English; diagnosis of a speech and/or language impairment; 
uncorrected poor vision or hearing; and a dominant left hand (to control for brain 
lateralization of language). All subjects had normal kidney function (eGFR greater than 
60 mL/min/1.73 m2), as assessed using the Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) equation (38). Differences in distribution of demographic 
factors between TPM dose groups introduced by randomization were tested using Chi-
squared tests for categorical variables and single factor ANOVAs for continuous 
variables. 
2.2.2 Modified Sternberg working memory task 
 Four hours post-dose at each treatment session, subjects completed a modified 
version of the Sternberg WM task (36). In this task a pronounceable non-word string of 
either one, three, or five syllables (referred to hereafter as “memory load”) was displayed 
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on-screen for 1.5 seconds. After this initial encoding period, the string was replaced by a 
fixation cross for 5 seconds, followed by presentation of a probe string which either 
matched the cue string or differed by a single letter. Subjects indicated whether the probe 
was the same or different from the cue string via button press, with “yes” and “no” 
responses randomized to different hands for each subject. A practice block was 
administered at the beginning of each session, followed by six blocks of 60 trials, with 
short breaks between each block to reduce fatigue. There were 120 trials of each memory 
load per session, with trials randomized by memory load. Response accuracy, which was 
calculated as the number of correct responses divided by the total number of responses 
for each memory load, was used as the pharmacodynamic endpoint for the analysis 
reported here.  
 Each subject’s working memory capacity (WMC) was estimated independently 
for each memory load from the data collected during their placebo visit using Cowan’s k 
equation (39), where k = N * (hit rate + correct rejection rate – 1), and N equals the 
memory load (1, 3, or 5). The value of k can be interpreted as a measure of the amount of 
information that can be concurrently held in memory and is a commonly used estimate of 
working memory capacity (40-43). 
 The effect of placebo and TPM on modified Sternberg WM task performance was 
compared to baseline using two-sided paired t-tests for each memory load to determine if 
there was a significant difference in task performance between drug sessions. Familywise 
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error rate was controlled using Bonferroni correction for the six comparisons, yielding a 
cutoff for significance at 0.0083 (α = 0.05/6 = 0.0083). 
2.2.3 Pharmacometric model development 
 A population pharmacokinetic model was first developed, which included PK 
samples from all subjects who completed a treatment visit during which they received 
TPM (n=40). An additional 14 subjects were included from a previous clinical trial 
performed in a similar population that utilized both an oral and IV formulation of TPM 
(25), which allowed us to better characterize the drug’s elimination phase. Allometric 
scaling was included on all clearances and volumes. 
 A sequential population pharmacokinetic-pharmacodynamic model was 
developed to fit the accuracy data from the modified Sternberg WM task. Only subjects 
who completed all study visits were included in this model (n=29). Linear, exponential, 
and Emax structural models were explored for drug effect, while an additive model was 
tested for placebo effect.  
 Models were implemented using nonlinear mixed effects modeling in NONMEM 
7.3 (ICON Development Solutions, Hanover, MD). Data exploration and diagnostic plots 
were created using R (version 3.4.1). Competing models were compared using the 
likelihood ratio test for nested models (dOFV > 3.84), and Akaike/Bayesian information 
criteria (AIC/BIC) for non-nested models. Model fit was assessed using goodness of fit 
plots of observations vs. predictions and residual plots. Adequacy of the final model was 
determined using prediction-corrected visual predictive checks, while precision of 
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estimates was verified using 1000 sample bootstrap simulations, both performed using 
Perl speaks NONMEM (PsN, version 4.7.0).  
 The effects of covariates on both pharmacokinetic and pharmacodynamic 
parameters were explored after determining the best-fitting structural model. Covariates 
explored for pharmacokinetic parameters included age, sex, creatinine clearance, and 
race; additionally, age, education, sequence of treatment, and WMC were explored for 
pharmacodynamic parameters. Covariates were tested using combined forward selection 
(p = 0.01) and backward elimination (p = 0.005) implemented with the SCM function in 
PsN.  
2.3 Results 
2.3.1 Subject demographics 
 Forty-six healthy volunteers provided written informed consent and completed all 
five study visits. Seventeen subjects had missing data due to errors in data acquisition or 
storage. The remaining twenty-nine subjects were included in the analysis presented here. 
Stratifying subjects by TPM dose did not reveal bias resulting from random assignment 
to dose group for any demographic variables (Table 1).  
2.3.2 Drug effects on working memory task performance 
 Administration of both placebo and TPM significantly reduced accuracy 
compared to baseline on the modified Sternberg WM task for all memory loads, with 
larger deficits produced by TPM administration (Figure 1). Performance on load one 
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trials was significantly (α = 0.0083) decreased from the baseline accuracy of 96.1% by 
placebo administration (91.2%, t28 = 3.9, p < 0.005) and TPM administration (87.5%, t28 
= 7.7, p < 5e-5). Similarly, load three accuracy was decreased from 91.4% during both 
placebo (86.8%, t28 = 4.4, p < 0.0005) and TPM sessions (80.9%, t28 = 8.6, p < 0.0001). 
Load five accuracy at baseline was 72.0%, which was significantly decreased by TPM 
administration (63.3%, t28 = 5.1, p < 0.0001), but not by placebo (69.0%, t28 = 2.5, p > 
0.008). 
2.3.3 Population pharmacokinetic model 
 The pharmacokinetic data were best fit by a two-compartment model (Table 2). 
Unlike previous models, a lag parameter was required to account for an absorption delay 
observed in approximately one-third of subjects. The NONMEM ALAG parameter with 
inter-individual variability was included in the model to obtain more accurate estimates 
of plasma concentrations at the hour four blood draw. Both Cmax and tmax of TPM are 
historically reported to be affected by fed status (44), but including subject-reported fed 
status in the model resulted in poorer fit compared to models using the ALAG parameter. 
Pharmacokinetic parameters were not significantly influenced by any covariates after 
allometric scaling of clearance and volume terms. 
2.3.4 Pharmacokinetic-pharmacodynamic model 
 The effect of TPM plasma concentration on WM task accuracy was best fit using 
a linear model with a unique intercept for each memory load. The following model 
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equation was used to predict accuracy on the modified Sternberg WM task after 
administration of TPM: 
WMTaskAccuracyijl = Interceptil ∗ (WMCnorm,il)
θCOV
− θTPM ∗ e
ηi ∗ Cpij − θPBO ∗ (WMCnorm,il)
θCOV
 
where Interceptil refers to the predicted baseline accuracy without placebo or TPM 
administration for individual i at memory load l, WMCnorm,il refers to the normalized 
WMC of memory load l for individual i, and Cpij refers to the predicted plasma 
concentration for individual i at time j. 
 WMC was the only significant covariate identified, modulating subject 
performance for all three memory loads used in this WM task. These results show, as 
expected, that individuals with high capacity for larger memory loads outperformed all 
others (Table 3). The placebo effect was also modulated by WMC, with high capacity 
individuals exhibiting a smaller placebo effect than low capacity individuals (Table 3). 
 An additive placebo effect was included in the model to account for changes in 
accuracy during the placebo session relative to the baseline session. The magnitude of the 
effect was estimated to be a decrease of approximately 3% regardless of memory load for 
the typical subject, equivalent to the effect elicited at the predicted Cmax of a 50 mg dose 
of TPM. The model predicted a 3.6% decrease in WM task accuracy for each μg/mL of 
TPM plasma concentration for the typical subject (Table 3). This TPM-related deficit was 
equivalent for all memory loads after accounting for individual differences in WMC. A 
decrease in accuracy of 9.0% would thus be expected independent of memory load for 
the mean observed hour 4 plasma concentration of 2.5 μg/mL. 
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2.3.5 Model evaluation 
 Goodness-of-fit plots from the final model showed the model fit both the PK 
(Figure 2) and the PD observations well (Figure 3). The prediction-corrected visual 
predictive check showed that model simulation fit the observed data well for each load 
independently (Figure 4). 
2.4 Discussion 
 In this study we used a population modeling approach to better characterize the 
relationships between WMC, TPM exposure, and the magnitude of drug-related cognitive 
impairment. Whereas a previous study showed that high- and low-capacity individuals 
were differentially affected by TPM exposure (26), we showed for the first time that after 
accounting for differences in WMC and TPM exposure, cognitive side effects were 
equivalent for all individuals. We extended previous findings by developing a model 
capable of predicting the severity of an individual’s WM deficits given their WMC and 
TPM dose. Additionally, we found that WMC also played a role in determining the 
severity of impairment resulting from placebo administration. 
 Our data revealed an association between TPM exposure and the extent of 
cognitive impairment, a finding that has not been consistently replicated (1, 27-30). A 
recent study showed that TPM exposure correlates with severity of cognitive side effects 
in individuals with high WMC, but not in those with low WMC, indicating that WMC 
may explain some of the inter-individual variability in sensitivity to TPM (26). Our 
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results show that impairment is equivalent amongst individuals with the same TPM 
plasma concentration after accounting for differences in WMC, consistent with these 
findings. By using a pharmacokinetic-pharmacodynamic modeling approach we were 
able to demonstrate the unique role of TPM exposure and WMC in determining the 
severity of cognitive side effects. 
 Including covariate effects is common practice in PK-PD modeling; however, 
using it to show that baseline cognitive function affects the degree of drug-related 
impairment is a novel application of this method. Previous studies have shown that 
baseline function plays a role in predicting disease progression in Alzheimer’s disease 
(45-47), as well as cognitive impairment resulting from both aging and drug side effects 
(22, 26, 48, 49). However, this study marks the first time that covariate modeling has 
been used to quantify the role of baseline cognitive function in the severity of drug side 
effects. Unlike previous studies which show that TPM decreases performance on a 
neuropsychological task (24, 25), the results of this study show TPM’s effect specific to 
WM function because of the use of the Sternberg task to accurately measure a single 
cognitive domain. Thus, our study design combined with a population modeling approach 
allowed us to characterize the effects of TPM exposure on a specific cognitive domain 
after accounting for differences in baseline cognitive function.  
 Placebo administration significantly reduced task performance for all memory 
loads. Our investigation of the placebo effect on WM function parallels alcohol research, 
which has shown that expectancy for intoxication causes physical, behavioral, and 
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cognitive changes (50-54). Thus, the observed placebo effect in our study may have been 
induced by the expectation that the administered drugs would cause impairment due to 
the description of side effects in the informed consent. When tested as a covariate 
affecting the placebo effect, treatment order was not found to be significant, implying 
that the observed placebo effect was not related to the randomized order in which drugs 
were administered. Additionally, a prior study showed that WM function was impaired 
by placebo when subjects were not told the expected effect of the substance they were 
being administered (55). Interestingly, subjects in our study with higher WMC 
experienced less severe placebo-related behavioral changes than those with low WMC. 
Parker et al. previously reported that WMC, as estimated by the operation span task, 
modulated the placebo effect in a study of the misinformation effect (56). Although 
alternate tasks were used in our study to estimate WM capacity and placebo effect, the 
association appears to be robust to these differences.  
 Our study has several limitations which may prevent generalizability of the 
results. Firstly, the pharmacodynamic endpoint utilized was obtained from a small sample 
of task-naïve subjects. While we were unable to quantify any learning effect which took 
place over the course of the experiment, this does not preclude the possibility that 
improvements took place in subsequent sessions. Secondly, as evidenced by the 
variability in absorption rate within our population sample and the limited range of 
concentrations observed at the time of WM task administration, having subjects complete 
the WM task only once at four hours post-drug-administration may reduce our ability to 
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capture the heterogeneity in side effects. While the use of a lag parameter helped increase 
precision of predicted concentrations, future studies should utilize multiple 
pharmacodynamic observations over the course of the elimination phase to further 
describe the temporal dynamics of TPM-related cognitive impairment. Finally, this 
single-dose study was unable to capture clinically-relevant concentrations such as those 
seen in patients taking chronic doses of TPM (57-60). It is unclear how these effects 
would extrapolate to patients receiving chronic doses of TPM. These limitations may be 
addressed by future studies to determine how this drug effect presents in a patient 
population. 
2.5 Conclusions 
 This study demonstrated that the severity of TPM-related cognitive deficits 
depends partially on drug exposure and baseline cognitive function. By combining a 
unique study design with a population modeling approach, we were able to identify a 
concentration-dependent impairment which was equivalent across memory loads after 
accounting for differences in WMC. The results of this study indicate that consideration 
of both patient-related characteristics (such as WMC) and treatment-related factors (such 
as dose) may be important in developing individualized dosing algorithms which 




 The authors thank the subjects who participated in this trial, Characterizing and 
Predicting Drug Effects on Cognition (NCT01889602). Funding for this project provided 
by NINDS R01NS076665 awarded to S.E. Marino, NINDS P50NS16308 awarded to I.E. 




Table 2-1. Baseline subject demographics stratified by topiramate dose assignment (mg) 
Dose assignment group (mg) 100 150 200 p-value* 
N 10 10 9 
 
Age [mean (SD)] 26.0 (8.2) 27.0 (9.7) 23.8 (6.3) 0.69 
Sex = Male (%) 5 (50.0) 5 (50.0) 5 (55.6) 0.96 
Height (cm) [mean (SD)] 169.6 (4.9) 175.0 (10.5) 172.1 (7.6) 0.35 
Weight (kg) [mean (SD)] 78.7 (16.7) 77.6 (11.6) 78.5 (15.7) 0.98 
WMC, load 1 [mean (SD)] 0.77 (0.26) 0.82 (0.17) 0.88 (0.06) 0.41 
WMC, load 3 [mean (SD)] 2.13 (0.58) 2.12 (0.49) 2.38 (0.32) 0.43 
WMC, load 5 [mean (SD)] 1.64 (1.15) 2.03 (0.92) 2.05 (0.95) 0.61 
Education (%)    0.21 
High school graduate or equivalent 1 (10.0) 0 (0.0) 0 (0.0) 
 
Some college/some university 6 (60.0) 6 (60.0) 6 (66.7) 
 
Completed vocational training 0 (0.0) 2 (20.0) 0 (0.0) 
 
Received bachelor's degree/university degree 1 (10.0) 2 (20.0) 3 (33.3) 
 
Any post-graduate education 2 (20.0) 0 (0.0) 0 (0.0) 
 
Race (%) 
   
0.23 
American Indian/Alaska Native 0 (0.0) 1 (10.0) 0 (0.0) 
 
Asian 0 (0.0) 0 (0.0) 2 (22.2) 
 
Asian & Black 0 (0.0) 0 (0.0) 1 (11.1) 
 
Black/African American 2 (20.0) 2 (20.0) 0 (0.0) 
 
White 8 (80.0) 7 (70.0) 6 (66.7) 
 




Table 2-2. Population pharmacokinetic model parameters 










CL (L/h) 1.1 7.3 1.1 (1.0, 1.2) 31.8 12.1 14.1 
Vc (L) 51.1 4.8 50.8 (46.3, 56.5) 16.6 8.1 5.4 
Vp (L) 12.9 13.1 13.0 (10.3, 19.0) 
   
Q (L/h) 1.2 34 1.2 (0.7, 2.3) 
   
Ka (h-1) 2.8 16.2 2.8 (2.1, 3.8) 136.3 12.9 18.3 
ALAG1 (h) 0.4 7.1 0.4 (0.4, 0.5) 69.6 16.1 19.7 
F1 1.1 2.9 1.1 (1.1, 1.2) 
   
Proportional 
RUV 
0.01 22.5 0.009 (0.006, 0.014) 
   
Abbreviations used in table: CL = clearance; Vc = volume in central compartment; Vp = volume in 
peripheral compartment; Q = intercompartmental clearance; Ka = first-order absorption rate constant; 
ALAG1 = absorption lag into the depot compartment; F1 = oral bioavailability; RUV = residual unexplained 























Intercept, Load 1 (%) 0.98 0.5 0.98 (0.97, 0.99) 
   
Intercept, Load 3 (%) 0.92 0.7 0.92 (0.91, 0.93) 
   
Intercept, Load 5 (%) 0.72 1.1 0.72 (0.70, 0.73) 
   
Drug Effect Slope 
(%/μg/mL) 
0.036 12.6 0.036 (0.027, 
0.045) 
50.7 32.6 13.1 
Placebo Effect (%) 0.036 19.8 0.034 (0.021, 
0.050) 
   
CK_1 on Intercept, 
Load 3 
-0.11 18.6 -0.12 (-0.30, -
0.069) 
   
CK_3 on Intercept, 
Load 3 
0.36 8.9 0.37 (0.28, 0.44) 
   
CK_1 on Intercept, 
Load 5 
-0.29 16.5 -0.30 (-0.40, -0.17) 
   
CK_5 on Intercept, 
Load 5 
0.21 8.1 0.21 (0.18, 0.26) 
   
CK_1 on Intercept, 
Load 1 
0.099 38 0.10 (0.043, 0.23) 
   
CK_3 on Intercept, 
Load 1 
0.091 43.5 0.080 (0.0068, 
0.16) 
   
CK_1 on Placebo 
Effect 
-0.99 11.3 -1.09 (-4.81, -0.82) 
   
Additive RUV 0.001
5 
10.5 0.0014 (0.0010, 
0.0017) 
   
Abbreviations used in table: CK_n = Cowan’s k estimate of working memory capacity for memory load n; 
RUV = residual unexplained variability; RSE = relative standard error, (standard error ÷ estimate) x 100; 








Figure 2-1. Accuracy results for the modified Sternberg working memory task from 
subjects who completed all study visits (n=29). Accuracy presented as percent correctly 
identified stratified by memory load. Memory load refers to the number of syllables in 
the remembered string. Points outside of the 1.5xIQR marked as individual points. 
Bonferroni correction for multiple comparisons was performed, resulting in an alpha of 




Figure 2-2. Goodness-of-fit plots for the final population pharmacokinetic 
model.Individual observations are denoted by closed circles, with trend lines indicated by 
the solid line. There were not any noteworthy trends which would indicate a problem 





Figure 2-3. Goodness-of-fit plots for the final population pharmacokinetic-
pharmacodynamic model.Individual observations are denoted by closed circles, with 
trend lines indicated by the solid line. There were not any noteworthy trends which would 




Figure 2-4. Prediction-corrected visual predictive check stratified by memory load for the 
final pharmacokinetic-pharmacodynamic model.Individual observations are represented 
by filled circles, with simulated prediction interval median denoted by a solid red line, 
and 5th & 95th percent simulated prediction intervals represented by solid blue lines. 
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 Topiramate (TPM) is a second-generation antiepileptic drug (AED) prescribed for 
migraine prophylaxis, treatment of epilepsy (1), obesity (2), substance abuse (3-7), and 
mood disorders (8, 9). Between 10 and 40 percent of patients taking TPM experience a 
variety of cognitive side effects (10-14), which can be severe enough to lead to 
discontinuation of treatment (15, 16). Studies have shown that multiple cognitive systems 
can be negatively impacted by TPM, including language, psychomotor function, and 
working memory (17-25). In the previous chapter we showed that performance on a 
Sternberg working memory task, which requires subjects to store varying amounts of 
information is working memory over short time intervals, was impaired by TPM in a 
concentration-dependent manner. However, additional insights into the nature of these 
deficits may be uncovered through investigation of TPM-related changes to 
electrophysiological activity. 
 Electroencephalography (EEG) is a commonly used neuroimaging technique with 
sufficient temporal precision to quantify changes in neural activity occurring on the scale 
of milliseconds (26). For a comprehensive review of this topic, readers can refer to the 
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Section 1.4.2 of this thesis. In this analysis, we aimed to quantify the effects of TPM 
exposure on spectral power in the theta band of the EEG recorded while healthy 
volunteers performed a modified Sternberg WM task. Electrophysiological activity in the 
theta frequency band has previously been shown to be a reliable index of WM function 
(27-31). In the Sternberg task specifically, theta power has been studied extensively 
during the retention phase of the Sternberg WM task (32-38) compared to the encoding 
and retrieval phases. As theta band power is known to be modulated by the amount of 
information retained in WM during Sternberg task performance, we hypothesized that 
TPM’s known effects on WM function would be reflected in changes in theta power as a 
result of drug administration.  
 We employed a non-linear mixed effects modeling approach with the goal of 
determining whether there exists a concentration-dependent modulation of theta band 
power following TPM administration. Pharmacokinetic-pharmacodynamic modeling has 
previously been used to assess the concentration-dependent changes in 
electrophysiological activity associated with drug efficacy (39-45). The benefit of using 
this modeling approach is that it can account for differences between subjects and yield a 
model which can make predictions about impairment at a population-level as well as 
incorporating and quantifying between-subject variability. Here we apply this approach 
to determine if theta band power varies as a function of TPM concentration, and whether 




3.2.1 Study population 
Healthy volunteers were recruited from the University of Minnesota and 
surrounding communities. The study was approved by the University of Minnesota 
Institutional Review Board, and informed consent was obtained from subjects prior to 
enrollment in the trial. Subjects were at least 18 years old at the time of enrollment, right 
hand dominant, and native speakers of English. Women under 50 years old were required 
to be either post-menopausal or using an approved form of birth control and were 
administered a pregnancy test during the no-drug baseline visit and at each treatment 
visit. Subjects were excluded if they reported having any of the following conditions: 
previous diagnosis of cardiovascular, endocrine, hematopoietic, hepatic, neurologic, 
psychiatric, or renal disease; a history of drug or alcohol abuse; use of concomitant 
medications known to affect cognitive function; prior history of hypersensitivity to TPM, 
lorazepam, or related compounds; use of any investigational drug within the previous 
thirty days; diagnosis of a speech or language impairment; or uncorrected poor vision or 
hearing.  
3.2.2 Study design 
 The study design has been reported in detail in chapter two of this thesis. Briefly, 
subjects were enrolled in a double-blind crossover study conducted at the University of 
Minnesota. Enrolled subjects completed a no-drug baseline visit during which their 
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electroencephalogram (EEG) was recorded while they completed a modified Sternberg 
WM task (46). Each individual was randomized to a treatment order for the subsequent 
three visits during which they received a single dose of either TPM (100, 150, or 200 
mg), lorazepam (2 mg), or placebo (lorazepam results not included in the analyses 
reported herein). TPM plasma concentrations were quantified using a validated LC/MS 
assay (47) from blood samples obtained during each treatment session at approximately 
0.5, 1.5, 2.5, 4, and 6 hours after dosing, and during a randomly assigned tail visit 
occurring either 24, 48, 72, or 96 hours post-dose. During each of the treatment sessions 
at approximately four hours after drug administration, subjects completed the modified 
Sternberg WM task described below. 
3.2.3 Modified Sternberg Working Memory Task 
 Working memory function was assessed during the baseline session and at each 
treatment visit using a modified Sternberg WM task (46). This task is used to investigate 
three distinct memory processes that occur during WM task performance: encoding, 
retention, and retrieval. During the encoding phase individuals are shown a 
pronounceable non-word string (cue) for 1.5 seconds, followed by the retention phase, in 
which a blank screen appears for 5 seconds. The retrieval phase begins once the probe 
string appears, and subjects are required to respond whether the probe is the same as the 
cue via handheld buttons which were randomized to different hands for each subject. The 
subject’s response, or lack of one within five seconds, triggers the onset of the next trial. 
Three memory loads, represented by strings of either one, three, or five syllables, were 
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used in the task. The experiment consisted of 360 total trials, comprised of 120 trials per 
memory load. Trials were randomized as a function of memory load and were presented 
in blocks of 60 with short breaks between blocks to prevent fatigue. Accuracy (the 
number of correct responses divided by the number of trials with responses) and reaction 
time (time between probe onset and a correct response) were recorded for each memory 
load.  
3.2.4 EEG collection and analysis 
 High-density EEG data were recorded throughout the modified Sternberg working 
memory task by a trained technician in a soundproof and electrically shielded chamber 
using a 128-channel EGI System (Electrical Geodesics Inc., Eugene, OR, USA) with an 
online sampling rate of 1 KHz. As suggested by the manufacturer, impedances were kept 
below 50 KΩ. Stimulus presentation and recording of behavioral responses were 
controlled using E-prime software (Psychology Software Tools, Inc., Pittsburgh, PA, 
USA). 
 Data pre-processing was performed in MATLAB (version R2018b, The 
Mathworks, Natick, MA, USA) using the EEGLAB toolbox (48). Recording epochs from 
the retention phase of correct trials of the modified Sternberg task were first down-
sampled to 250 Hz and high pass filtered at 1 Hz. Five second epochs were extracted 
time-locked to cue offset, incorporating 500 msec baseline and 5000 msec following cue 
offset. The data were cleaned in the following steps: bad channels were removed and 
subsequently re-interpolated, the data were re-referenced to the average of activity at all 
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electrodes, 60 Hz line noise and its’ harmonics were removed using the CleanLine 
function (available from https://www.nitrc.org), and the resulting data were entered into 
independent components analysis (ICA). ICA was performed twice; artifactual 
components were rejected manually after both the first and second iterations of ICA. Fast 
Fourier transforms were then applied to the cleaned data in order to provide estimates of 
spectral power in the following traditional frequency bands: theta (4-8 Hz), alpha (8-13 
Hz), lower beta (13-20 Hz), upper beta (20-30 Hz), and gamma (30-80 Hz). Power was 
calculated over regions of interest spanning six spatially contiguous electrodes over 
frontal (theta, lower & upper beta), central (gamma), and posterior (alpha) scalp sites. 
 Measures of absolute theta power obtained during the placebo and TPM sessions 




This transformation resulted in a continuous variable where zero represented no change 
from baseline, positive values a fractional increase in power from baseline, and negative 
values a fractional decrease in power from baseline. Using this approach to analyze the 
EEG data offered three distinct advantages: (i) controlling for baseline differences in 
power between subjects, (ii) permitting the detection of placebo effects through non-zero 
change scores observed during the placebo session, and (iii) reducing the number of 
outliers in the EEG data to be modeled by normalizing the distribution of the data.  
 Exploratory analysis using R (version 3.4.1) revealed larger theta power change 
scores with increasing TPM plasma concentrations, with all three memory loads 
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displaying a similar trend in this relationship (Figure 1). This pattern of results motivated 
the decision to deviate from the modeling approach used with the behavioral data in 
chapter two, in which each memory load was modeled separately. Instead, theta power 
change scores were averaged across all three memory loads, and the mean was used as 
the pharmacodynamic endpoint in the model described below. 
3.2.5 Pharmacokinetic-pharmacodynamic model development 
 A sequential PK-PD model was developed to associate TPM plasma 
concentrations with theta power change scores using a nonlinear mixed-effects model 
implemented in NONMEM (version 7.4.3, ICON Development Solutions, Hanover, MD, 
USA). The estimates from the two-compartment population PK model (n=54) closely 
matched previously reported values in a similar population (49), and have been discussed 
in detail in the second chapter of this thesis. A linear model was used to approximate the 
relationship between TPM plasma concentration and theta power change scores. Though 
this likely over-simplifies the relationship between the two variables, an exploration of 
structural models other than a linear relationship was precluded by the sparsity of EEG 
recordings from each subject (one observation from the placebo session and one 
observation from the TPM session, both converted to a change from baseline score). This 
limitation prevented identification of any time lag effect, or exploration of more realistic 
relationships between plasma concentration and theta power change, including turnover, 
transduction, exponential, piecewise linear, or Emax models (50, 51). 
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 During exploratory analysis of our dataset, we observed large variability in theta 
power change as a function of TPM plasma concentration (Figure 1). Motivated by this 
large variability, we attempted to identify a covariate which would correlate with 
sensitivity of theta power to TPM exposure but were unable to identify any useful 
correlates. Thus, we implemented a mixture model to assess the possibility of two distinct 
subpopulations with differing sensitivity to TPM-related theta power changes. A mixture 
model assigns individuals to one of multiple unique subpopulations, with each 
subpopulation characterized by different model parameters (52). The $MIX routine in 
NONMEM classifies individuals using an empirical Bayesian algorithm conditioned on 
the individual’s data and post hoc population parameter estimates (52, 53). This 
unsupervised clustering algorithm assumes multiple populations exist within the observed 
dataset, and probabilistically assigns individuals to one of the subpopulations while also 
estimating the parameters defining the subpopulations (54). If multiple subpopulations do 
not exist in the dataset, there will be no significant difference between the parameter 
estimates for the two groups. 
 An Individual PK Parameters with Standard Errors (IPPSE) modeling approach 
was applied in this chapter. In this sequential modeling approach, conditional means and 
variance estimates for all PK parameters containing ETAs are obtained from the root.phi 
file output by the population pharmacokinetic run (52). Including this information in the 
PK-PD model allows propagation of PK parameter estimate uncertainty into the 
estimation of PD parameters. Parameter uncertainty may be a result of an unequal 
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number of observations between individuals, which may be important to the model 
presented here because individuals in the population PK analysis had between zero and 
two observations below the assay quantification limit of 0.375 ug/mL (47). Inclusion of 
the uncertainty from the PK parameters estimates increases PD parameter precision and 
decreases bias in a manner similar to simultaneous and Population PK Parameters and PK 
Data (PPP&D) modeling approaches, while also benefiting from run times ~60% shorter 
compared to the simultaneous approach (55). IPPSE allows increased parameter estimate 
precision with decreased bias compared to the Individuals PK Parameters (IPP) method 
used in chapter two, which assumes that the empirical Bayes estimates from the 
population PK model are estimated without error (55). Although the IPP and 
simultaneous methods are more commonly used, the IPPSE method is a useful 
compromise between the estimate precision offered by the simultaneous method and the 
shorter runtimes offered by the IPP method. 
 The existence of potential practice effects was explored by adapting an approach 
previously applied to practice effects on the SDMT (56). Number of previous tests 
administered (NPT) was included as a step function affecting the model intercept using 
the following equation: 
𝐼𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡𝑖 = 𝑇𝑉𝐼𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡 ∗ 𝐼𝑁𝑃𝑇≥𝑛 ∗ θ𝑁𝑃𝑇≥𝑛 
where INPT≥n is a binary value indicating whether the number of previous tests is greater 
than or equal to the threshold n, and θNPT≥n is the multiplicative effect on the intercept for 
visits meeting this criterion. Different values were tested for the threshold n 
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encompassing the three possible values in the study design (e.g. on the third visit n = 2, 
as the task has been completed twice previously). Lack of effect of subsequent visits is 
indicated by θNPT≥n being equal to one. 
 All models during the model building process were evaluated using goodness-of-
fit plots and compared using the likelihood ratio test (χ2, α= 0.05, df = 1, dOFV > 3.84) or 
Akaike/Bayesian information criteria (AIC/BIC) for nested and non-nested models, 
respectively. Covariate effects were explored using sequential forward selection (p = 
0.01) and backward elimination (p = 0.005) implemented with the SCM function in Perl 
speaks NONMEM (PsN, version 4.7.0). The final model fit was evaluated using 
prediction-corrected visual predictive checks, and precision of final parameter estimates 
were evaluated using 1000 sample bootstrap simulations, both performed using PsN. 
3.2.6 Behavioral differences between mixture populations 
 Significant differences between the two population mixtures, for both accuracy 
and reaction time, were tested using two-factor sequential analysis of variance (Type 1 
ANOVA) which included an interaction term between memory load and population 
mixture estimate from the mixture model (described in PK-PD modeling section). Post 
hoc non-parametric Mann-Whitney U tests were also used to compare theta band power 




3.3.1 Subject demographics 
 Forty-six subjects completed all visits in the protocol; however, due to data loss 
resulting from errors in either acquisition or storage, data from only twenty-seven 
subjects are reported here (Table 1). 
3.3.2 Pharmacometric model results 
 Two distinct subpopulations were identified by the mixture model, with each 
subpopulation defined by a different relationship between theta power and TPM plasma 
concentration (Figure 1, Table 2). Unique slope parameters were estimated, significantly 
improving the model fit (dOFV = -16.662, p < 0.0001). The group exhibiting a stronger 
relationship between power and concentration (i.e. steeper slope) were referred to as the 
“theta-reactive” group because they showed a larger change in theta power for equivalent 
drug exposure relative to the “theta-unreactive” subpopulation, who showed a flatter 
slope. Eight individuals (37.5%) were predicted by the mixture model to be part of the 
theta-reactive subpopulation, while 19 individuals (62.5%) were predicted to be part of 
the theta-unreactive subpopulation (Table 2). Magnitude of theta power change in the 
theta-reactive group was eightfold more sensitive to TPM plasma concentrations 
compared to the theta-unreactive group (0.66 ug/mL vs. 0.082 ug/mL; Table 2). 
Stratifying subjects by mixture model subpopulation assignment did not reveal any 
significant demographic differences between the two groups (Table 1). 
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 Differences were not observed between mixture populations on the PBO visit, so 
the same model intercept was used for both subpopulations. The intercept value shared 
between the two subpopulations, which indicates the change score from baseline on the 
placebo visit, was significantly different from zero (95% CI = 0.00047 - 0.325), 
indicating a slight placebo effect (Table 2, Figure 2).  
 Number of previous tests was found to be a significant covariate in the final 
model, with power in the typical subject 51% greater on visit three compared to the 
previous two visits (Table 2). Addition of this practice effect significantly improved the 
model (dOFV = -4.803, p < 0.05). Results from the bootstrap indicate that this effect was 
estimated with poor precision, as evidenced by the 95% CI crossing the null effect value 
of 1 (Table 2). 
 The final model predicted theta power change from baseline using the following 
equation: 
𝑇ℎ𝑒𝑡𝑎𝑃𝑜𝑤𝑒𝑟𝑖,𝑗,𝑚 = θ𝑖𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡 ∗ θ𝑣𝑖𝑠𝑖𝑡,𝑗 ∗ (1 + θ𝑒𝑡𝑎𝑠𝑐𝑎𝑙𝑒 ∗ η1) + θ𝑠𝑙𝑜𝑝𝑒,𝑚 ∗ 𝐶𝑝𝑝𝑟𝑒𝑑,𝑖,𝑗 ∗ (1 + η1) + ϵi,j 
where θintercept is the predicted theta power change score for the placebo session in the 
typical subject (which should be zero if no placebo effect is present), θvisit refers to the 
multiplicative increase in theta power at visit 4 compared to prior visits, θetascale refers to 
the difference in scale between inter-individual differences in intercept and slope 
(included due to correlation near 1 when separate etas for slope and intercept were used), 
θslope,m refers to the slope for mixture m, Cppred,i,j refers to the predicted plasma 
concentration for individual i at time j, and ϵi,j refers to residual unexplained variability 
for individual i at time j. 
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 Visual predictive checks revealed that the model adequately described the data for 
both subpopulations (Figure 2). Goodness-of-fit plots confirmed that no consistent bias 
due to model misspecification was present (Figure 3). 
3.3.3 Behavioral differences between empirically identified subpopulations 
 Differences in behavioral performance of the two subpopulations identified by the 
mixture model were compared for each of the three memory loads independently using 
two-factor ANOVA. Although the two groups did not differ in their response accuracy, 
there was a statistically significant difference in their reaction time (Figure 4). Theta-
unreactive individuals on average responded 276 msec slower (1614 +/- 61.0 msec vs. 
1338 +/- 94.1 msec) than the theta-reactive individuals after adjusting for differences due 
to memory load, a difference of approximately 20% compared to the theta-reactive 
response time (F1,75 = 6.05, p < 0.05). The interaction between memory load and 
population mixture estimate was not significant (F2,75 = 0.08, p > 0.05). Post hoc Mann-
Whitney U tests were used to compare groups for each memory load because the data 
violated the assumption of equal variance. Reaction time differences were not significant 
in the non-parametric analysis for any of the three memory loads. This inconsistency is 
likely due to the lack of a non-parametric equivalent to two-factor ANOVA which can 
account for differences in reaction time due to memory load. 
  Mann-Whitney U tests were implemented to determine whether baseline 
differences in theta power existed between mixtures (Figure 5). At baseline, theta-
reactive individuals exhibited significantly lower theta power than theta-unreactive 
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individuals (p < 0.05); this pattern was reversed at the TPM visit, with the theta-reactive 
group showing significantly higher theta power (p < .0001). There were no significant 
differences in theta power between the two subpopulations observed during the placebo 
visit. 
3.4 Discussion 
 In this study we showed that oscillatory power in the theta frequency band 
recorded during the retention phase of a modified Sternberg task increased linearly as a 
function of TPM plasma concentration. Using a mixture model, we identified two distinct 
subpopulations who differed eightfold in their sensitivity of theta power to TPM 
concentrations. These electrophysiological differences also mapped onto differences in 
behavior on the Sternberg WM task, with reaction time being significantly different 
between the two groups after adjusting for differences due to memory load. An 
electrophysiological correlate of practice, manifesting as increased band power as a 
function of the number of previous times the subject performed the task, was observed in 
both groups. A small placebo effect was also observed, as was the case with the 
behavioral results reported in chapter two.  
 The mixture model identified two subpopulations defined by sensitivity of an 
electrophysiological measure to TPM. The existence of varying levels of sensitivity to 
TPM-related side effects is in line with previous reports of high variability in side effects 
within the population taking the drug (10-13, 20, 23); however, the extent to which theta 
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activity and the incidence of cognitive side effects is related is unclear. Stratifying 
behavioral results by the subpopulations defined by electrophysiological sensitivity 
showed that the theta-unreactive group responded significantly slower than the theta-
reactive group on the modified Sternberg WM task. Interestingly, there was no 
population-level effect of TPM on reaction time in a previous analysis of these data (18). 
This implies that the slowing effect present in the theta-unreactive group is masked by the 
patients who experience minimal TPM-related impairment.  
 One possible explanation for the difference in behavioral response between these 
groups may be that the theta-reactive group is increasing their mental effort following 
TPM administration in order to overcome TPM-induced cognitive insult. Mental effort 
has been previously defined by Paas et al. as “the aspect of cognitive load that refers to 
the cognitive capacity that is actually allocated to accommodate the demands imposed by 
the task” (57). Overcoming performance impairment resulting from stressors such as 
noise, sleep deprivation, or a cognitive insult, may be accomplished by increasing mental 
effort (58, 59). Theta power is frequently cited as an index of mental effort (60-64), as 
evidenced by its consistent increase with memory load during the Sternberg task, for 
example (32-36, 38). According to this interpretation, the large theta power increases in 
reaction time in response to TPM exposure in the theta-reactive group may reflect 
increased mental effort, allowing these individuals to maintain similar performance levels 
as in drug-free sessions. This behavioral pattern is contrasted with subjects in the theta-
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unreactive subpopulation, who exhibit minimal changes in theta power in response to 
TPM exposure, and thus are unable to overcome TPM’s negative impact on cognition.  
 An alternative explanation for the behavioral differences between the theta-
reactive and theta-unreactive groups is that they differ in terms of neural efficiency. The 
neural efficiency hypothesis states that high-functioning individuals show less brain 
activation than low-functioning individuals while completing the same task (65, 66). 
Theta power at baseline was lower in the theta-reactive group than the theta-unreactive 
group (Figure 5), consistent with the idea that theta-reactive individuals have a greater 
degree of neural efficiency. In response to TPM exposure, theta power increases in the 
theta-reactive group, while reaction times on the Sternberg task remain similar to those 
observed during drug-free conditions. Meanwhile, neural resources are being used less 
efficiently by the theta-unreactive group, resulting in an inability to increase resource 
allocation to overcome the TPM-related cognitive insult, which results in slower response 
times on the Sternberg task. This hypothesis is supported by a previous study which 
showed that TPM impairs neural efficiency as manifested in larger mid-latency ERP 
component amplitudes and recruitment of additional neural resources following TPM 
administration while holding memory load constant (67). Thus, it may be the case that the 
behavioral differences between subpopulations are due to a ceiling effect which prevents 
the theta-unreactive group from allocating additional resources to maintain optimal task 
performance following TPM exposure. 
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 A neurophysiological correlate of a practice effect was observed in both 
subpopulations which manifest as a 51% increase in theta power on the fourth completion 
of the task relative to power measurements during previous visits. This increase in theta 
power as a result of multiple test administrations was not sufficient to cause differences 
in accuracy on the Sternberg task, as evidenced by a lack of practice effect observed in 
the behavioral pharmacokinetic-pharmacodynamic model presented in Chapter 2. One 
plausible interpretation of these findings is that individuals have learned the structure of 
the Sternberg task trials after completing 1080 trials over the course of the previous three 
study visits. The probe stimulus is presented once the retention phase ends after exactly 
five seconds, and the increased activity is occurring just prior to probe stimulus display in 
preparation for comparison with the cue stimulus. To determine if this hypothesis is 
correct one might look at the EEG data as event-related potentials (ERP) to visualize the 
temporal dynamics underlying the increase in theta power change during the retention 
phase of the Sternberg task. Previous studies of this phenomenon have termed it the 
contingent negative variation (68-70), and it has been reported during the retention phase 
of the Sternberg task (71-73). Alternatively, theta power has also been described as an 
index of attention and cognitive control (74-77). This increased theta power on the final 
visit may reflect an increased burden on attentional resources resulting from subject 
boredom. Therefore, increased theta may reflect the subject’s attempt to stay attentive to 
a 90-minute task which they have previously completed three times. Further research 
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must be completed to determine whether increased theta power may reflect a practice 
effect. 
 Theta power increased by an average of 12.6% following placebo administration 
(Table 2). A placebo effect was also observed in behavioral measures of the modified 
Sternberg WM task (see Chapter 2), which showed that placebo administration resulted 
in a 3.6% decrease in accuracy; however, the relationship between the 
electrophysiological and behavioral indices is unclear at this point. Although few studies 
have investigated electrophysiological indices of the placebo effect, there is some 
evidence that both theta and alpha power (78, 79) are affected by placebo administration. 
 One limitation of this study is the exclusion of EEG measures obtained during 
incorrect trials of the Sternberg task. Although these trials were not analyzed because 
there are many reasons why a subject may give an incorrect response (e.g. not paying 
attention, errors in either encoding or retrieval of the cue stimulus, misreading either the 
cue or probe stimuli, etc.), using only electrophysiological measurements during correct 
trials leaves us unable to characterize changes taking place during incorrect trials. 
Inclusion of all measurements coded as correct/incorrect may allow a more accurate 
representation of the differences in behavior between individuals, for example looking at 
power change differences within a treatment session between correct and incorrect trials. 
Furthermore, this data censoring is especially impactful for load five observations, 
resulting in a loss of up to 48% of observations for poorly-performing individuals. 
Another limitation is the use of healthy volunteers taking a single dose of TPM. Although 
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these are clinically relevant doses, steady-state concentrations will be higher during 
chronic dosing. Patients taking the drug may exhibit different electrophysiological 
responses to TPM, especially activity related to the condition for which the drug was 
prescribed. Patients may adjust to the presence of the drug over time, and compensatory 
mechanisms may manifest during chronic dosing. There is also potential for drug 
interactions to play a role in cognitive side effects in patients taking multiple medications. 
 In conclusion, our results show that two distinct subpopulations existed which 
differed in their change in theta band power as a function of TPM exposure by a factor of 
ten, with changes in electrophysiological activity correlating with performance on a 
modified Sternberg WM task. Further studies are necessary to determine if the 
electrophysiological changes exhibited may provide insight into the mechanism through 
which TPM-related cognitive impairment occurs. 
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Table 3-1. Population demographics 







N 8 19  
TPM Dose (%)   0.099 
100 mg 1 (12.5) 8 (42.1)  
150 mg 2 (25.0) 7 (36.8)  
200 mg 5 (62.5) 4 (21.1)  
Age (years) (mean (sd)) 24.00 (6.16) 26.63 (9.00) 0.459 
Education (%)   0.734 
Some college/some university 5 (62.5) 12 (63.2)  
Completed vocational training 0 (0.0) 2 (10.5)  
Received bachelor’s degree/university degree 2 (25.0) 4 (21.1)  
Any post-graduate education 1 (12.5) 1 (5.3)  
Sex = Male (%) 5 (62.5) 9 (47.4) 0.767 
Weight (kg) (mean (sd)) 76.39 
(15.31) 
80.14 (14.36) 0.549 
eGFR (mL/min/1.73 m^2) (mean (sd)) 78.48 (3.39) 79.60 (6.89) 0.669 
Race (%)   0.301 
American Indian/Alaska Native 0 (0.0) 1 (5.3)  
Asian 2 (25.0) 1 (5.3)  
Black/African American 0 (0.0) 3 (15.8)  




Table 3-2. PK-PD model results 
Parameter Estimate RSE (%) Bootstrap Median Bootstrap 95% CI 
Theta Intercept 0.126 71.8 0.129 (0.00047, 0.325) 
Population 1 
Slope (μg/mL) -1 
0.664 10.4 0.674 (0.489, 0.866) 
Population 2 
Slope (μg/mL) -1 
0.0821 39.0 0.0796 (0.0163, 0.173) 
Population 1 Mix 
Fraction 
0.358 31.6 0.370 (0.132, 0.629) 
Eta Scale Factor 12 66.8 12.2 (3.5, 1613.7) 
Visit ≥ 3 Practice 
Effect 
1.51 15.9 1.46 (0.444, 2.04) 
IIV Intercept & 
Scaled-Slope 
0.758 46.3 0.806 (0.0062, 0.283) 







Figure 3-1: Change in EEG power as a function of topiramate plasma concentration for 
all subjects (n=27).Loess smooth lines use a smoothing parameter of 0.75, with memory 
loads 1, 3, and 5 represented by solid, short-dashed, and long-dashed lines, respectively. 
Thin solid lines connect mean observations from individuals during their placebo and 
topiramate sessions, with observations labeled according to mixture estimate of Theta-





Figure 3-2. Prediction-corrected visual predictive checks for the two subpopulations. 
Filled circles represent observed theta power change score relative to baseline vs. model-
predicted TPM plasma concentrations. Solid and dashed lines represent median and 
5th/95th percentile, respectively. Colored ribbons depict 95% confidence interval about the 





Figure 3-3. Goodness-of-fit plots for final population pharmacokinetic-pharmacodynamic 
model.Individual observations are denoted by closed circles, with trend lines indicated by 
the solid line. There were not any noteworthy trends which would indicate a problem 




Figure 3-4. Comparison of Sternberg task accuracy (A) and reaction time (B) for three 
memory loads stratified by mixture population estimate. Population 1 (theta-reactive) 
group is shown in light gray, and population 2 (theta-unreactive) is shown in dark gray. 
Outliers, as defined by observations > 1.5*inter-quartile range, are represented by closed 
circles. A statistically significant difference between subpopulations was identified for 




Figure 3-5. Comparison of theta power for each visit between mixture population 
estimates.Population 1 (theta-reactive) group is shown in light gray, and population 2 
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 When modeling drug-induced changes to physiological processes, there are two 
options available for selecting indices of drug effect: relying on indices identified by 
previous research, or using a data-driven approach to empirically select an optimal 
measure. Application of a literature-driven approach may result in selection of sub-
optimal indices of drug effects when investigating previously under-studied phenomena. 
Investigations into the effects of topiramate (TPM) on WM function are an ideal case for 
the application of a data-driven approach, as limited research has been conducted into 
the possible indices of impairment. In the previous chapter, we showed that theta power 
observed during the retention phase of a modified Sternberg WM task increases linearly 
as a function of TPM plasma concentration. In this case, we based our selection of 
spectral power in the theta frequency band on the rich literature illustrating how this 
electrophysiological activity is positively correlated with the amount of information held 
in WM (1-7). However, there are additional electrophysiological indices of WM 
function that may be sensitive to TPM exposure, including (i) theta power seen during 
the encoding and retrieval stages of the Sternberg WM task (8-10), and (ii) power in the 
93 
 
alpha frequency band observed during encoding, retention, and retrieval processes (1, 3, 
5, 7, 11-19). Although these measures are plausibly sensitive to TPM-related WM 
impairment, the dearth of existing research investigating the effects of TPM on any of 
these measures made it difficult to determine whether this would in fact be the case. As 
a result, we relied on existing literature and investigated the relationship between 
retention-related theta power and TPM exposure. We therefore applied a post hoc data-
driven approach to investigate whether theta power observed during retention in WM 
was the optimal marker for TPM-induced WM impairment, and better understand how 
results from a data-driven selection of electrophysiological endpoints would differ from 
a literature-driven selection. 
 Principal component analysis (PCA) is an unsupervised machine learning 
algorithm primarily used for dimensionality reduction in large datasets. This technique 
takes a set of possibly-correlated variables and uses a linear combination of these 
variables to form principal components (PCs), such that each PC maximizes explained 
variability and is orthogonal to the other PCs. The motivation for this transformation is 
to explain as much of the variability in the data using as few variables as possible. This 
approach yields PCs that can replace the original variables while minimizing the amount 
of information lost and reducing degrees of freedom for predictive modeling. PCA has 
been applied in biomedical research in a number of ways, including identifying latent 
factors in medical records (20), determining therapeutic sensitivity of tumors subtyped 
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using genomic markers (21), and clustering expression patterns in microarray assay 
results (22). 
 One limitation of PCA is that variable weights for each PC are typically nonzero, 
resulting in a linear combination of all input variables in each PC. PCs composed of 
loadings of all variables in the original data set are often difficult to interpret. However, 
this limitation may be overcome through application of shrinkage methods, which 
facilitate empirical selection of subsets of data. Variable shrinkage is not a primary 
result of standard PCA, but a modified version of PCA called “sparse principal 
component analysis” (SPCA) uses a combination of ridge regression and least absolute 
shrinkage selection operator (LASSO) to shrink loadings of variables toward zero (23). 
Thus, PCs identified by SPCA retain weights on only a subset of the variables, 
facilitating a more straightforward interpretation of which aspects of the data are 
meaningfully reflected in each PC. SPCA has been previously applied to dense 
electroencephalography (EEG) data in brain-computer interface applications as a method 
of component selection and feature extraction (24). 
 In this analysis, we applied a SPCA-based analysis with the goal of identifying 
the EEG-derived measures obtained during a modified Sternberg task that would be 
most sensitive to TPM administration. Although theta power observed during the 
retention phase of the Sternberg task was found to be modulated by TPM exposure (see 
Chapter 2), our aim was to assess whether this was the optimal index of TPM-related 
cognitive deficits. It is possible that a linear combination of EEG-derived measures 
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identified by SPCA would be a better indicator of impairment and that this type of 
composite measure would provide additional insights into the mechanism(s) 
underpinning TPM-related cognitive side effects. 
4.2 Methods 
4.2.1 Study design 
 The electroencephalography (EEG) data included in this analysis is identical to 
the data modeled in Chapter 3, which was collected during the clinical protocol first 
described in Chapter 2. Briefly, healthy volunteers were recruited for a crossover study 
of TPM’s negative impact on cognition. A modified Sternberg WM task (25) and a 
neuropsychological battery were administered at a drug-free baseline visit. Subjects 
were randomly assigned to receive a single dose of either TPM (100 mg, 150 mg, or 200 
mg), lorazepam (2 mg), or inactive placebo on three subsequent treatment visits. 
Subjects completed the neuropsychological battery at approximately 0.5, 2.5, and 6 
hours after dosing, and during a tail visit randomly assigned to occur either 24, 48, 72, or 
96 hours after dosing on each treatment visit, while the Sternberg task was administered 
approximately 4 hours after dosing at each treatment visit. 
4.2.2 Digit span task 
 In addition to the Sternberg WM task, the digit span forward and backward tasks 
(DSF and DSB, respectively) are also commonly used to assess WM function (26-29). 
These tasks were administered multiple times for each subject as part of the 
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neuropsychological battery (see Chapter 2 for protocol details). DSF is a simple span 
task, evaluating the storage component of WM, while DSB is a complex span task, 
evaluating both storage and manipulation of objects in WM (27, 30). In both tasks, 
subjects are verbally presented a three-digit long string of random numbers. In the DSF 
task, the subject repeats back the numbers verbatim, whereas in the backward task the 
subject repeats back the numbers in reverse order. After two successfully recalled strings 
of a given length, the length of the string was increased by one, up to a maximum string 
length of nine for DSF and eight for DSB. Each correct response is worth one point 
when scoring the tasks. If the subject does not correctly recall a string of digits for a 
given string length, a second string of the same length was given. Two sequential 
failures to repeat a string of a given length results in the task being terminated by the test 
administrator. The mean tmax in our pharmacokinetic data was 2.49 +/- 1.42 hours, 
motivating our choice of analyzing DSF/DSB scores from the hour 6 post-dose 
neuropsychological battery instead of hour 2.5 results. TPM concentrations at hour 6 
should be most similar to hour 4, when the Sternberg task was administered, because the 
majority of subjects are past the absorption phase, resulting in a smaller change in 
concentration over time. 
4.2.3 Electroencephalogram recording and analysis 
 EEG recordings from correct trials of the modified Sternberg WM task were 
analyzed separately for each stage of the task. One second encoding epochs were time-
locked to cue stimulus onset, including 200 msec prior to onset and 1000 msec 
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following onset. Five second retention epochs were time-locked to cue stimulus offset, 
including 500 msec prior to offset and 5000 msec following offset. Three second 
retrieval epochs were time-locked to probe stimulus onset, including 500 msec prior to 
onset and 3000 msec following onset. These data were analyzed using an identical 
method as that described in detail in Section 3.2.4 of this thesis. Absolute spectral band 
power for both the frontal theta (4 – 8 Hz) and posterior alpha (8 – 12 Hz) frequency 
bands from each of the encoding, retention, and retrieval phases of the Sternberg WM 
task were calculated separately for each of the three memory loads, resulting in a total of 
18 EEG measurements per visit per individual. All EEG measurements were then 




This transformation simplifies interpretation as positive values indicate an increase in 
power from baseline after TPM administration, and negative values a decrease. 
Furthermore, standardizing the data using this approach increases validity of the results 
of subsequent analyses by converting measures to the same scale (31). A correlation 
matrix was calculated for all power change scores in order to determine the correlation 
structure within and across frequency bands. 
 Multivariate regressions using spectral power change scores from the theta and 
alpha frequency bands as regressors were constructed to quantify the extent to which 
electrophysiological measurements predicted performance on the modified Sternberg 
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task, and to assess the interpretability of these results. Accuracy and reaction time were 
each regressed separately on theta and alpha power change scores. 
4.2.4 Principal component analysis 
 Sparse principal component analysis (SPCA) was implemented to handle the 
small sample size and to facilitate interpretation of PCs. This technique uses the elastic 
net, a penalized least-squares method commonly used in multiple linear regression as a 
variable selection technique to drive regressor loadings to zero when possible (23). 
Elastic net combines two different penalty terms to allow correlated predictors: 1-norm 
LASSO (least absolute shrinkage and selection operator (32)) penalty and a quadratic 
ridge penalty. LASSO and ridge penalty are both shrinkage methods which minimize 
regression coefficients; however, only LASSO results in zero loadings on variables. 
These shrinkage methods are both driven by selection of a tuning parameter, a penalty 
term which shifts weights of a fraction of the predictors to zero. The number of nonzero 
predictors is negatively correlated with the tuning parameter, which is typically chosen 
using a cross-validation approach. The result of SPCA is that variables which make 
minimal contributions to explaining variability are excluded. According to the “elbow 
method” for determining the number of PCs to retain (33), only one PC was 
recommended to be retained; however, five total PCs were retained to maximize the 
potential for identifying meaningful relationships between electrophysiological 
measures and behavior in the subsequent regression analyses (described in the following 
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section). SPCA was implemented using the spca() function in the elasticnet R package 
(34) in R (version 3.4.1) (35). 
 Five-fold cross validation was performed to determine the optimal tuning 
parameters for both the ridge regression penalty and LASSO penalty in the SPCA 
analysis. The spca() function uniquely implements the 1-norm LASSO tuning parameter 
in a way that allows a specified number of predictors to be retained within each PC, with 
the remaining regressor weights driven to zero. Competing tuning parameters were 
compared during the five-fold cross validation using a residual sum of squares as the 
cost function. 
 Behavioral measures from the Sternberg task were regressed on the first five PCs 
generated by SPCA in order to determine whether these linear combinations of EEG-
derived measures would provide improved prediction of task performance compared to 
simple spectral power change scores. DSF score was also regressed on the first five 
sparse PCs to investigate whether electrophysiological measures obtained during the 
Sternberg task would be predictive of performance on a separate task assessing WM 
function. Statistical significance for the regression models was set at p < 0.05. 
4.3 Results 
4.3.1 Multivariate regression of theta and alpha power change scores 
 Four multivariate regression models examining relationships between spectral 
power change scores and performance on the modified Sternberg WM task were 
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analyzed: i) theta power regressed on accuracy, ii) theta power regressed on reaction 
time, iii) alpha power regressed on accuracy, and iv) alpha power regressed on reaction 
time. Although theta power during the encoding and retention phase was predictive of 
accuracy, regression coefficients were not consistent between loads within a task phase 
(Table 1, Figure 1A). Likewise, some theta power measures from the retention phase 
were predictive of reaction time, but not all (Table 2, Figure 1B). No alpha band power 
regression coefficients were significantly different from zero when used to predict 
accuracy or reaction time on the Sternberg task (results not shown).  
 Correlations between EEG measures were calculated in order to determine the 
suitability of multivariate regression analysis for this data (Figure 2). High correlations 
between independent regressors may cause regression coefficients to be unstable, 
motivating the need to use a dimensionality reduction technique such as PCA (31). 
Within a given phase of the WM task and frequency band (e.g. theta power during the 
retention phase), spectral power change scores were highly correlated (r ≥ 0.8) across 
memory loads. High correlation was also observed across phases of the WM task in both 
the theta (0.22 ≤ r ≤ 0.72) and alpha (0.84 ≤ r ≤ 0.98) bands. Theta power during the 
retention phase was correlated with alpha power across all phases of the WM task and 
for each memory load (0.42 ≤ r ≤ 0.68). These high correlations show that the data were 
did not meet the statistical assumptions required for a multivariate regression analysis. 
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4.3.2 Principal components analysis 
 SPCA was conducted to reduce the dimensionality of the dataset (Table 3). PCA 
was also applied to the data but offered limited interpretability, further motivating use of 
SPCA (results not shown). The optimal LASSO tuning parameter identified during the 
five-fold cross validation retained nine variables in each PC, decreasing the number of 
retained regressors by 50% while maintaining a similar percent of variability explained 
by each of the first five PCs (Figure 3). The first principal component, comprising 
activity in the alpha band for all loads and all phases of the WM task, explained more 
than 80% of the variability in theta and alpha spectral power (Figure 3). 
4.3.3 Sternberg behavioral measures regressed on principal components 
 Accuracy and reaction time data collected during the modified Sternberg WM 
task were regressed on the five PCs identified by SPCA. In the accuracy model, none of 
the slopes of the five PCs were significantly different from zero, with a coefficient of 
determination less than 11% (results not shown). In the reaction time model, PC 4, 
primarily comprised of activity in the theta band during the retention period, was the 
only regressor trending toward significance (Table 4, p < 0.1). Goodness-of-fit plots 




4.3.4 Digit Span score regressed on principal components 
 Score on DSF and DSB were tested as outcome variables in models using the 
SPCA-derived PCs as regressors. In the model in which DSF score was regressed on the 
five sparse PCs, the third component was found to be a significant regressor (Table 5, p 
< 0.05). PC 3 was primarily defined by activity in the alpha band during the encoding 
and retrieval phases of the Sternberg task. The measure associated with reaction time on 
the Sternberg task, PC 4, also trended toward significance in the DSF model (Table 5 p 
< 0.1). In the model constructed to account for the relationship between PCs and DSB 
performance, none of the PC regressors reached statistical significance (results not 
shown). Goodness-of-fit plots revealed that DSF scores were fit well by the regression 
model (Figure 5). 
4.4 Discussion 
 In this chapter, we demonstrated the application of a data-driven approach to 
selecting electrophysiological indices of TPM-related WM impairment. The results are 
consistent with the endpoint selected based on a limited amount of previous research. 
Although it explained less than 3% of the variability in the electrophysiological data, 
theta activity observed during the retention period (PC 4) predicted both reaction time 
on the modified Sternberg task and score on the DSF task. SPCA showed that over 80% 
of variability in the electrophysiological data collected was explained by activity in the 
alpha band across stages of the Sternberg WM task (PC 1), but that this activity was not 
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predictive of performance. However, a combination of alpha activity recorded during the 
encoding and retrieval stages (PC 3) of this task was the best predictor of score on the 
DSF task. 
 Few previous studies have been conducted to determine the electrophysiological 
indices of drug-induced WM impairment, so in order to determine which measures were 
likely to be modulated by TPM exposure, we turned to activity in the theta (1-10) or 
alpha (1, 3, 5, 7, 11-19) frequency bands because of their sensitivity to memory load 
effects. Theta power during the retention phase of the Sternberg task was selected as the 
pharmacodynamic endpoint in Chapter 3 based on the extensive literature which showed 
that this measure was sensitive to memory load changes in studies involving no 
pharmacological manipulation. However, it was unknown whether theta power was the 
optimal marker of TPM-related impairment due to the lack of existing literature on this 
phenomenon. Interestingly, the unsupervised machine learning algorithm presented here 
showed that theta band power during WM retention was in fact the optimal 
electrophysiological index of impairment. Application of SPCA showed that alpha 
power observed at each stage of the WM task was the most variable of the 
electrophysiological measures analyzed here. Despite this, the first PC, defined entirely 
by alpha activity at all stages of the modified Sternberg WM task, was not a significant 
predictor of performance on the Sternberg task. This illustrates that, though widely 




 Linear combinations of theta and alpha power recorded during the modified 
Sternberg WM task correlated with performance on the DSF task, another test 
commonly used to evaluate WM function. In the DSF task, subjects have to retain, but 
not manipulate, a string of digits. Likewise, during the retention phase of the Sternberg 
task, subjects are tasked with maintaining representations of the string of syllables and 
are not manipulating or comparing this information. It is therefore unsurprising that 
electrophysiological activity during the retention phase of a modified Sternberg task 
would correlate with performance on the DSF task.  
 Regression using sparse PCs also found that PC 3, primarily defined by alpha 
activity during the encoding and retrieval phases of the Sternberg task, was predictive of 
performance on the DSF task. Recall that PC 3 is separate from and orthogonal to PC 1, 
which is defined by alpha activity at all stages of the Sternberg task and accounts for 
over 80% of the variability in the electrophysiological data. Results of the regression 
showed that increased alpha power during encoding predicted higher DSF scores, while 
increased alpha power during the retrieval phase predicted lower DSF scores. Increased 
alpha power during memory encoding has previously been associated with increased 
memory performance in healthy volunteers (36, 37), consistent with the results 
presented here. WM retrieval processes have received less attention in the literature 
compared to the encoding and retention phases; however, one previous study also found 
alpha power during retrieval was negatively correlated with memory performance (37). 
There are numerous differences between the DSF and Sternberg tasks, which may 
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explain why alpha activity predicts performance on DSF, but not on the Sternberg task. 
It is possible that the lack of correlation between alpha power and reaction time is due to 
the dual speed-accuracy requirements of the Sternberg task, commonly termed the 
speed-accuracy trade-off (38), through which behavioral deficits can manifest as either 
decreased accuracy or increased reaction time. Furthermore, there is an impetus for 
subjects to respond quickly in DSF, due to the rapid degradation of memory 
representations. Finally, the to-be remembered stimuli are presented differently between 
these two tasks: verbally in DSF and visually in the modified Sternberg, a difference that 
has consequences for all WM functions. Because of the many differences in these two 
tasks, it is unsurprising that they are not defined by identical electrophysiological 
correlates of performance. 
 There were several limitations to our study. Spectral power in the theta and alpha 
band were selected due to the large literature describing their relation to WM function; 
however, a multitude of electrophysiological measures are also known to correlate with 
WM , such as P2 amplitude (39), P300 amplitude (40), theta-gamma amplitude coupling 
(41, 42), alpha-gamma coupling (17, 43), alpha phase (14, 43) and alpha peak frequency 
(4). These measures were not analyzed here due to an inability to reliably extract these 
variables from the type of noisy EEG data associated with drug administration, but it 
may be advantageous to incorporate some of these additional electrophysiological 
indices of WM function in future studies. Additionally, the cross-validation method used 
to identify the optimal number of nonzero variables in the sparse PCA assumed the same 
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number of variables should be included in each PC. This simplification was adopted due 
to the exponential increase in computational time if the number of retained variables in 
each PC can vary independently. For example, imposing this limitation allowed for 
minimization of tuning parameters across a two-dimensional surface, rather than the six-
dimensional surface which would exist had each of the five retained PCs been allowed 
to vary independently. Although it did not affect interpretation of PCs, the inadequacy of 
this assumption can be seen in PC 4, which has large weights on the retention phase 
measures, and near zero measures for four of the remaining six retained variables.  
 In conclusion, this analysis demonstrated the utility of an unsupervised machine 
learning algorithm for the identification of electrophysiological markers of TPM-related 
cognitive side effects, especially because of the limited research previously conducted in 
this area. Although the optimal measure identified using this novel method matched the 
measure previously selected after surveying the existing literature (see Chapter 2), 
agreement between these two approaches was not a foregone conclusion. This type of 
analysis may be productive in future studies during early stages of the drug development 
process when investigating a novel therapeutic with multiple possible drug effect 





Table 4-1. Multivariate regression of accuracy (%/100) on a modified Sternberg working 
memory task as a function of absolute midline theta power change score. 
 Estimate Std. Error t value Pr(>|t|) 
Intercept -0.059 0.019 -3.119 0.007* 
Thetaencoding, load 1 -0.150 0.094 -1.595 0.131 
Thetaencoding, load 3 0.028 0.042 0.685 0.504 
Thetaencoding, load 5 0.113 0.045 2.500 0.025* 
Thetaretention, load 1 -0.082 0.044 -1.867 0.082† 
Thetaretention, load 3 -0.095 0.057 -1.658 0.118 
Thetaretention, load 5 0.157 0.067 2.345 0.033* 
Thetaretrieval, load 1 0.068 0.051 1.320 0.207 
Thetaretrieval, load 3 -0.005 0.078 -0.071 0.945 
Thetaretrieval, load 5 -0.060 0.068 -0.880 0.393 






Table 4-2. Multivariate regression of reaction time (msec) on a modified Sternberg 
working memory task as a function of absolute midline theta power change score. 
 Estimate Std. Error t value Pr(>|t|) 
Intercept 0.138 0.047 2.928 0.010* 
Thetaencoding, load 1 0.245 0.235 1.043 0.313 
Thetaencoding, load 3 -0.215 0.104 -2.075 0.056† 
Thetaencoding, load 5 0.060 0.113 0.528 0.605 
Thetaretention, load 1 0.191 0.109 1.747 0.101 
Thetaretention, load 3 0.327 0.143 2.289 0.037* 
Thetaretention, load 5 -0.632 0.167 -3.778 0.002* 
Thetaretrieval, load 1 0.071 0.128 0.552 0.589 
Thetaretrieval, load 3 0.140 0.193 0.723 0.481 
Thetaretrieval, load 5 -0.216 0.170 -1.270 0.223 





Table 4-3. Principal component weights for sparse principal component analysis. 
Frequency Memory Stage Load PC 1 PC 2 PC 3 PC 4 PC 5 
Theta Encoding 1 - -0.2555 0.0094 - - 
Theta Encoding 3 - -0.5288 0.0816 -0.1059 - 
Theta Encoding 5 - -0.3911 0.022 - 0.0976 
Theta Retention 1 - -0.0476 - 0.3368 - 
Theta Retention 3 - - - 0.6608 - 
Theta Retention 5 - - - 0.6413 - 
Theta Retrieval 1 - -0.4462 -0.1027 0.1576 -0.1097 
Theta Retrieval 3 - -0.3465 - - - 
Theta Retrieval 5 - -0.4228 - - - 
Alpha Encoding 1 0.3288 - -0.1425 - - 
Alpha Encoding 3 0.2922 - -0.7833 -0.0368 -0.1218 
Alpha Encoding 5 0.1505 - -0.4206 0.0259 - 
Alpha Retention 1 0.1937 0.0089 - - 0.4221 
Alpha Retention 3 0.1667 - - - 0.4624 
Alpha Retention 5 0.0696 - - 0.0224 0.603 
Alpha Retrieval 1 0.6247 - 0.3561 0.0003 -0.2062 
Alpha Retrieval 3 0.5344 - 0.2114 - -0.1918 





Table 4-4. Multivariate regression of reaction time (msec) on a modified Sternberg 
working memory task as a function of sparse principal components. 





Intercept 0.106 0.062 1.723 0.101 
PC 1 0.004 0.010 0.366 0.718 
PC 2 -0.027 0.031 -0.847 0.408 
PC 3 -0.049 0.043 -1.142 0.268 
PC 4 -0.082 0.043 -1.925 0.069† 
PC 5 -0.025 0.053 -0.461 0.650 




Table 4-5. Multivariate regression of digit span forward as a function of sparse principal 
components. 





Intercept -0.319 0.044 -7.185 0.000* 
PC 1 -0.001 0.007 -0.074 0.942 
PC 2 -0.012 0.023 -0.531 0.602 
PC 3 -0.075 0.031 -2.410 0.026* 
PC 4 -0.055 0.031 -1.770 0.093† 
PC 5 -0.029 0.038 -0.762 0.455 







Figure 4-1. Goodness-of-fit plots for multivariate regression models of theta power band 
vs Sternberg behavioral results.Observed vs predicted accuracy (a) and reaction time (b) 






Figure 4-2. Correlation between EEG absolute power change in theta and alpha bands 
during the encoding, retention, and probe phase of a modified Sternberg working memory 
task separated into three memory loads.Plot created using Dr. Julian Wolfson’s 






Figure 4-3. Scree plot comparing explained variances of principal component analysis 





Figure 4-4. Goodness-of-fit plot for multivariate regression models of sparse principal 
components vs Sternberg reaction time (msec) results.Observed vs predicted plot 





Figure 4-5. Goodness-of-fit plot for multivariate regression models of sparse principal 
components vs digit span forward.Observed vs predicted plot includes line of unity for 
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 The analyses presented in this thesis demonstrate the multifaceted effects of 
topiramate (TPM) on working memory (WM). The major goals of this thesis were to 
characterize the changes to behavioral and electrophysiological indices of WM processes 
resulting from TPM exposure and to determine how these indices are related to one 
another. To achieve this goal, a combination of non-linear mixed effects models and 
machine learning algorithms were constructed to determine i) the effects of TPM on 
behavior, ii) the effects of TPM on brain responses, and iii) how electrophysiological and 
behavioral changes in response to TPM are associated with one another. 
5.1 Effects of topiramate on behavior 
 We identified a concentration-dependent relationship between TPM exposure and 
the severity of performance deficits on a modified Sternberg WM task. As stated 
throughout this thesis, the Sternberg task has been used for decades to quantify WM 
function. This specificity allowed us to understand the effects of TPM on this 
neurocognitive system in particular, rather than being limited to broad statements 
regarding its effect on subjects’ performance on tasks that simultaneously assess multiple 
aspects of cognition. Our motivation for focusing on the WM system is its correlation 
with numerous measures of high-level cognitive processes, including math skills (1, 2), 
reading comprehension (2, 3), fluid intelligence (4, 5), and verbal fluency (6-9). In the 
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results reported here, we showed that the magnitude of TPM-related impairment was 
partially determined by both WM capacity (WMC) and TPM plasma concentration, but 
independent of the amount of information held in WM after accounting for differences in 
WMC. Although this is not the first time that WMC has been associated with the severity 
of TPM-induced cognitive deficits (10), we improved upon previous findings by 
developing a tool which can make predictions about the severity of WM deficits prior to 
drug administration given an individual’s WMC and TPM dose. 
5.2 Effects of topiramate on brain responses 
 We showed for the first time that the magnitude of spectral power observed 
during the retention phase of the Sternberg WM task increased linearly as a function of 
TPM plasma concentrations. Even though subjects were exposed to TPM levels much 
lower than would be expected from chronic dosing in patients with epilepsy (11), 
significant changes in electrophysiology were still observed in response to drug 
administration. Furthermore, a subset of individuals was particularly sensitive to the 
electrophysiological effects of TPM, showing eightfold greater increases in theta power 
as plasma concentration increased. Reaction times on the Sternberg task differed 
significantly between these two subpopulations, indicating that sensitivity to TPM 
affected not only electrophysiology, but also behavioral measures of task performance.  
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5.3 Relationship between electrophysiological and behavioral changes 
 Some of the most compelling findings presented in this thesis are those that 
showed that brain and behavioral responses are not always linked in predictable ways as 
one might expect; changes in brain responses do not always co-occur with observable 
changes in behavior. Although over 80% of the variability in the EEG data was explained 
by differences in alpha power, we did not find alpha power to predict performance on the 
Sternberg task. Alpha power varies widely between individuals depending on age, mental 
state, and the task being performed (12-14). Although previous studies show that alpha 
power correlates with WM function (15-20), our approach demonstrated that it is not 
sensitive to TPM-induced impairment of WM function. In contrast, less than three 
percent of the variability in the EEG data was explained by differences in theta power 
during the retention phase of the WM task. Although much less variable than alpha 
power, this narrow range of variability was the best predictor of task performance. 
Characterizing the interaction between activity in the theta and alpha bands following 
TPM administration and their association with behavioral outcomes remains a topic for 
future research. 
 We observed a practice effect in the electrophysiological data (Chapter 3), while 
there was no evidence of a behavioral practice effect (Chapter 2). The 
electrophysiological index of this practice effect was an increase in theta power during 
the retention stage of the Sternberg task when comparing the final study visit to previous 
visits. We hypothesized that this increased activity reflects anticipation of the time-locked 
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display of the probe stimulus: after completing over 1000 trials of the task, individuals 
developed an ability to predict the occurrence of the probe stimulus onset which 
occurred, consistently and exactly, five seconds after cue stimulus offset. The lack of a 
practice effect observed in the accuracy results may imply that this electrophysiological 
index of a practice effect is either i) not related to task performance, or ii) related to 
reaction time on the Sternberg task rather than accuracy.  
 Though not consistently, there were also instances in which changes in 
electrophysiology were mirrored by behavioral changes. Although at the population level 
it was shown that there is no effect of TPM on reaction time in the Sternberg task (10), 
analysis of subgroups based on sensitivity of theta power to TPM did show an effect 
(Chapter 3). The group defined by lower theta reactivity as a function of TPM exposure 
performed the Sternberg task slower than their high sensitivity counterparts. These 
subpopulations were not visible in the pharmacokinetic-pharmacodynamic model of the 
accuracy data, indicating that analyzing the Sternberg accuracy and reaction time results 
may be necessary because deficits can manifest through either measure.  
 A negative effect of placebo administration on task performance, or a “nocebo 
effect,” was observed in both the behavioral (Chapter 2) and electrophysiological 
measures (Chapter 3) collected during Sternberg task performance. The ability to 
quantify the effect of placebo administration in a novel way was made possible by the 
crossover study design, which allowed us to separate the impairments occurring as a 
function of TPM exposure, and those corresponding to the nocebo effect. We 
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hypothesized that the nocebo effect was due to an expectancy bias resulting from the 
informed consent process, during which subjects were told that the goal of the study was 
to understand the negative impact of drugs on cognition. Interestingly, the magnitude of 
the nocebo effect was predicted by individual WMC in a manner similar to that seen in 
the drug effect. Limited research has been conducted into predictors of individual 
vulnerability to the placebo effect; however, one study found that expected improvement 
in cognition following placebo administration was modulated by WMC (21). Our results 
show that this relationship holds for negative placebo effects as well, highlighting the 
important role that expectancy plays in the effects of drugs on cognitive function.  
 The electrophysiological response to placebo exhibited large interindividual 
variability in magnitude and direction. Unlike the placebo effect observed in the 
behavioral results, the magnitude of these changes were not predicted by WMC. Due to 
the existence of distinct subpopulations with differing sensitivity to TPM, it is difficult to 
compare the TPM-related changes to electrophysiology with placebo-related changes. 
However, theta band power showed small increases following placebo administration, 
similar to those observed in the theta-unreactive group following TPM administration, 
with behavioral deficits observed in both instances. A possible interpretation of this result 
is that an electrophysiological measure not analyzed here is associated with behavioral 
deficits on the Sternberg task, while theta power plays a complementary role in 
overcoming these deficits. This would explain why the TPM-sensitive theta-reactive  
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group did not exhibit large behavioral differences with their large changes in theta power. 
One possible measure, which would also explain the observed association between 
behavioral measures of the placebo effect and WMC, is P300 amplitude, which has been 
previously shown to correlate with WMC (22, 23). Although there are limited studies on 
electrophysiological indices of the placebo effect, these results clearly indicate that there 
exists a relationship between spectral power and placebo-induced behavioral deficits.  
5.4 Future directions and concluding statements 
 The application of sparse principal component analysis (SPCA) in this thesis 
offers a unique proof of concept for investigations where physiological drug effect 
research is lacking. Prior to this research, there were limited published accounts of the 
effect of TPM on electrophysiological indices of WM function. Spectral power in the 
theta frequency band during the retention period of the Sternberg task was selected as the 
measure to be analyzed in Chapter 3 simply because of the previously reported sensitivity 
of theta power to manipulations of memory load; however, it was unknown if it would 
also be an index of the well-studied WM deficits caused by TPM. The results of the 
SPCA empirically confirmed theta power during retention to be the best predictor of 
TPM-related impairment, consistent with existing work. Although we completed the 
pharmacokinetic-pharmacodynamic modeling and the SPCA sequentially, SPCA could 
also be completed prior to modeling to inform variable selection in circumstances when 
there is a lack of clarity regarding the measure that should be used as the 
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pharmacodynamic endpoint. Moreover, linear combinations of multiple endpoints (i.e. 
PCs) identified by SPCA could be used as composite endpoints sensitive to the 
multifaceted effects of a drug on behavior and electrophysiology in downstream 
applications such as pharmacokinetic-pharmacodynamic models.  
 In summary, the quantitative pharmacological approach developed throughout 
this thesis provides a blueprint for future explorations into drug-induced cognitive 
impairment. Using this framework, I showed that TPM impairs behavioral performance 
on a WM task, and the magnitude of impairment is predicted by individual WMC. TPM 
also modulates an electrophysiological index of WM function, and certain individuals are 
more sensitive to TPM’s effect on electrophysiology. Furthermore, the 
electrophysiological measure modulated by TPM exposure predicted WM impairments. 
Two treatment-independent factors were identified using this approach, WMC and TPM 
sensitivity, which predict the magnitude of TPM-induced impairment. Future research 
can build upon these findings to develop a clinical tool using these measures to predict 
which patients are most likely to experience cognitive side effects prior to TPM 
administration, thus improving patient experience by avoiding prescribing of TPM in 
patients likely to experience cognitive side effects. 
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7.1 Chapter 2: Population Pharmacokinetic Model Control Stream 
$PROBLEM Topiramate 2-compartment PK Model with absorption lag 
$INPUT C ID TIME NTIME DV AMT RATE DRUG CMT MDV EVID WT AGE HT 
    SEX BSA LBM IBW BMI RACE0 RACE1 RACE2 RACE3 RACE4 
    RACE5 TSB FED1 FED15 FED2 FED25 FED3 FED35 FED4 
    
$SUBROUTINES ADVAN4 TRANS4 
 
$PK 
; shared iv/oral pk parameters 
TVCL = THETA(1) * (WT/70)**0.75 
CL = TVCL * EXP(ETA(1)) 
TVV2 = THETA(2) * (WT/70) 
V2 = TVV2 * EXP(ETA(3)) 
TVV3 = THETA(3) * (WT/70) 
V3 = TVV3 
TVQ = THETA(4) * (WT/70)**0.75 
Q = TVQ 
 
; oral pk parameters 
IF(DRUG.EQ.1) THEN 
TVALAG1 = THETA(6) 
ALAG1 = TVALAG1 * EXP(ETA(4)) 
TVKA = THETA(5) 










S2 = V2 
S3 = V3 
 
$ERROR 
IPRED = F 





(0, 1)   ; CL 
(0, 40)  ; VC 
(0, 20)  ; VP 
(0, 5)   ; Q 
(0, 0.5)  ; KA 
(0, 0.2)  ; ALAG1 
(0, .8)   ; F1 
 
$OMEGA 
0.1 ; IIV CL 
0.1 ; IIV KA 
0.1 ; IIV V2 
0.1 ; IIV ALAG1 
 
$SIGMA 
0.01 ; Proportional CV 
 
$ETAS FILE=output.phi 
$EST METHOD=1 INTERACTION MAXEVALS=9999 POSTHOC NOABORT NSIG=3 
SIGL=9 MCETA=1 
 





7.2 Chapter 2: Population Pharmacokinetic-Pharmacodynamic Model 
Control Stream 
$PROBLEM  Topiramate Direct Response PK-PD Model of Sternberg WM 
Task Accuracy 
$INPUT   C ID DATE=DROP CTIME=TIME DV SESSION VISIT LOAD AMT FLAG 
      AGE SEX HT WT EDU CKDEPI MDRD CG ETH RACE0 RACE1 RACE2 
      RACE3 RACE4 RACE5 CLI V2I V3I QI KAI ALAG1I F1I TAD MDV 
      EVID COMPLETE SEQ CK1 CK3 CK5 
$SUBROUTINE ADVAN4 TRANS4 
 
$PK 
; sequential PK parameter assignment 
CL = CLI 
V2 = V2I 
V3 = V3I 
Q = QI 
ALAG1 = ALAG1I 
KA = KAI 
F1 = F1I 
 
S2 = V2 
S3 = V3 
 
; covariate model from SCM (PsN) 
  PBOEFFECTCK1 = ((CK1/0.88)**THETA(12)) 
PBOEFFECTCOV=PBOEFFECTCK1 
 
  INTERCEPTCK3 = ((CK3/2.3)**THETA(11)) 
  INTERCEPTCK1 = ((CK1/0.88)**THETA(10)) 
INTERCEPTCOV=INTERCEPTCK1*INTERCEPTCK3 
 
  INT5CK5 = ((CK5/1.75)**THETA(9)) 
  INT5CK1 = ((CK1/0.88)**THETA(8)) 
INT5COV=INT5CK1*INT5CK5 
 
  INT3CK3 = ((CK3/2.3)**THETA(7)) 
  INT3CK1 = ((CK1/0.88)**THETA(6)) 
INT3COV=INT3CK1*INT3CK3 
 
; PD model parameters 
TVINTERCEPT = THETA(1) 
 
TVINTERCEPT = INTERCEPTCOV*TVINTERCEPT 




TVINT3 = INT3COV*TVINT3 
TVINT5 = THETA(3) 
 
TVINT5 = INT5COV*TVINT5 
TVDVSLOPE = THETA(4) 
TVPBOEFFECT = THETA(5) 
 
TVPBOEFFECT = PBOEFFECTCOV*TVPBOEFFECT 
 
$ERROR  
CP = F 
 
;;;;;; LOAD-specific Variable definition 
; LOAD 1 
IF(LOAD.EQ.1) THEN 
INTERCEPT = TVINTERCEPT 
DVSLOPE = TVDVSLOPE * EXP(ETA(1)) 
ENDIF 
 
; LOAD 3 
IF(LOAD.EQ.3) THEN 
INT3 = TVINT3 
INTERCEPT = INT3 
DVSLOPE = TVDVSLOPE * EXP(ETA(1)) 
ENDIF 
 
; LOAD 5 
IF(LOAD.EQ.5) THEN 
INT5 = TVINT5 
INTERCEPT = INT5 
DVSLOPE = TVDVSLOPE * EXP(ETA(1)) 
ENDIF 
 
;;;;;;;;; Drug Effect Model Subcomponent 
; Linear DVSLOPE 
DVS = CP*DVSLOPE 
 
;;;;;;;; Full Model 
EFF = INTERCEPT - DVS 
 
PBOEFFECT = TVPBOEFFECT 
; subtract placebo effect on placebo visit 
IF(SESSION.EQ.1) THEN 
EFF = EFF - PBOEFFECT 
ENDIF 
 







;;;;;; Residual Unexplained Variability 
Y = EFF + EPS(1) ; PD additive error 
 
$THETA  
; PD model parameters 
(0,0.9) ; Load 1 Intercept 
(0,0.9) ; Load 3 Intercept 
(0,0.7) ; Load 5 Intercept 
(0,0.1) ; Load 1,3,5 Drug Effect slope 
(0,0.1) ; Placebo Effect 
; covariate effects 
(-0.1) ; CK1 on Intercept Load 3 
(0.3)  ; CK3 on Intercept Load 3 
(-0.3) ; CK1 on Intercept Load 5 
(0.2)  ; CK5 on Intercept Load 5 
(0.1)  ; CK1 on Intercept Load 1 
(0.1)  ; CK3 on Intercept Load 1 
(-1.2) ; CK1 on Placebo Effect 
 
$OMEGA  
0.1   ; IIV on Load 1,3,5 DVSLOPE 
 
$SIGMA  
0.1   ; PD additive error 
 
$ESTIMATION METHOD=1 INTERACTION MAXEVALS=9999 POSTHOC NOABORT 
NSIG=3 SIGL=9 
 




7.3 Chapter 3: Population Pharmacokinetic-Pharmacodynamic 
Control Stream 
$PROBLEM  Topiramate EEG Indirect PK-PD Model 
$INPUT   C ID DATE=DROP TIME DV SESSION VISIT LOAD AMT FLAG 
      AGE SEX HT WT EDU CKDEPI MDRD CG ETH RACE0 RACE1 RACE2 
      RACE3 RACE4 RACE5 CLI V2I V3I QI KAI ALAG1I F1I TAD MDV 
      EVID COMPLETE SEQ CK1 CK3 CK5 CKA SECL SEKA SEV2 SEALAG1 
 
$SUBROUTINE ADVAN4 TRANS4 
 
$PK 
CL = CLI*EXP(ETA(2)*SECL) 
V2 = V2I*EXP(ETA(3)*SEV2) 
V3 = V3I 
Q = QI 
ALAG1 = ALAG1I*EXP(ETA(4)*SEALAG1) 
KA = KAI*EXP(ETA(5)*SEKA) 
F1 = F1I 
 
S2 = V2 
S3 = V3 
 
$ERROR 
;---- Drug Effect Model 
; assign Cp for drug effect model 
CP = F 
; save system variable 
EST = MIXEST 
; create CK mean variable 
CK = (CK1 + CK3 + CK5) / 3 
 
VISITEFF = 1 
IF(VISIT.GE.3) THEN 
VISITEFF = THETA(6) 
ENDIF 
 
; shared baseline 
BL_tPower = THETA(1) * VISITEFF * (1 + THETA(5) * ETA(1)) 
 
; mixture model for drug slope 
IF(MIXNUM.EQ.1) THEN 
TVSLOPE1 = THETA(2) 
SLOPE = TVSLOPE1 * (1 + ETA(1)) 
ELSE 
TVSLOPE2 = THETA(3) 
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SLOPE = TVSLOPE2 * (1 + ETA(1)) 
ENDIF 
 
; effect = slope * concentration 
EFF= SLOPE*CP 
 
;---- Full Model 
tPower = BL_tPower + EFF 
IPRED = tPower 
 
;---- Residual Error Model 
Y = tPower + EPS(1) 
 
$MIX 
P(1) = THETA(4) 




0.5 ; BL tPower 
(0, 2); SLOPE POP1 
(0, 0.5) ; SLOPE POP2 
(0, 0.5, 1) ; MIX POP1 
(1)  ; ETA-SCALE 
(1)   ; VISIT4 
 
$OMEGA 
0.1 ; IIV BL 
1 FIX ; SECL 
1 FIX ; SEV2 
1 FIX ; SEALAG1 
1 FIX ; SEKA 
 
$SIGMA 
0.5 ; AddRUV 
 
$ESTIMATION METHOD=1 INTERACTION MAXEVALS=9999 POSTHOC NOABORT 
NSIG=3 SIGL=9 




7.4 Chapter 3: Spectral Power Calculation EEGLAB Script 
function f = powerCalc(EEG) 
 
  % multiple channel locations 
  [spectra1,freqs1] = spectopo(EEG.data([19 10 12 5 11],:,:), 0, 
EEG.srate); 
  thetaSpec = mean(spectra1); % frontal theta 
  [spectra2,freqs2] = spectopo(EEG.data([61 79 67 78 68],:,:), 0, 
EEG.srate); 
  alphaSpec = mean(spectra2); % posterior alpha 
  [spectra3,freqs3] = spectopo(EEG.data([7 107 32 81 129],:,:), 0, 
EEG.srate); 
  gammaSpec = mean(spectra3); % central gamma 
  [spectra4,freqs4] = spectopo(EEG.data([19 10 12 5 11],:,:), 0, 
EEG.srate); 
  betaSpec = mean(spectra4); % frontal beta 
   
  thetaIdx = 5:9; 
  alphaIdx = 9:13; 
  beta1Idx = 13:21; 
  beta2Idx = 21:31; 
  gammaIdx = 31:81; 
 
  % compute power specific to each frequency ROI 
  thetaPower = mean(10.^(thetaSpec(thetaIdx)/10)); 
  alphaPower = mean(10.^(alphaSpec(alphaIdx)/10)); 
  beta1Power = mean(10.^(betaSpec(beta1Idx)/10)); 
  beta2Power = mean(10.^(betaSpec(beta2Idx)/10)); 
  gammaPower = mean(10.^(gammaSpec(gammaIdx)/10)); 
 
   
  f = [thetaPower alphaPower beta1Power beta2Power gammaPower]; 
end 
 
 
